[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3318
1. Blum AE, Walsh BC, Dubyak GR: Extracellular osmolarity modulates G protein-coupled receptor-dependent ATP release from 1321N1 astrocytoma cells. Am J Physiol Cell Physiol; 2010 Feb;298(2):C386-96
Hazardous Substances Data Bank. PROBENECID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular osmolarity modulates G protein-coupled receptor-dependent ATP release from 1321N1 astrocytoma cells.
  • We previously reported that ATP release from 1321N1 human astrocytoma cells could be stimulated either by activation of G protein-coupled receptors (GPCR) or by hypotonic stress.
  • Thus, we provide the new finding that GPCR-regulated ATP release from 1321N1 astrocytoma cells is remarkably sensitive to both positive and negative modulation by extracellular osmolarity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Channels (Austin). 2009 Sep-Oct;3(5):323-36 [19713739.001]
  • [Cites] J Neurochem. 2008 Jun 1;105(6):2260-70 [18315563.001]
  • [Cites] J Physiol. 2007 Oct 15;584(Pt 2):419-35 [17702822.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Dec;23(6):755-61 [11104728.001]
  • [Cites] J Physiol. 2001 May 1;532(Pt 3):759-69 [11313444.001]
  • [Cites] J Gen Physiol. 2001 Sep;118(3):251-66 [11524456.001]
  • [Cites] J Membr Biol. 2002 Jan 15;185(2):93-102 [11891568.001]
  • [Cites] J Gen Physiol. 2002 Jun;119(6):511-20 [12034759.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Aug;283(2):C569-78 [12107067.001]
  • [Cites] J Neurochem. 2003 Jan;84(1):3-9 [12485396.001]
  • [Cites] Acta Physiol Scand. 2003 Feb;177(2):119-47 [12558550.001]
  • [Cites] J Neurophysiol. 2003 Apr;89(4):1870-7 [12686569.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23331-42 [12684505.001]
  • [Cites] Mol Pharmacol. 2003 Oct;64(4):785-95 [14500734.001]
  • [Cites] Neurochem Res. 2004 Jan;29(1):239-46 [14992283.001]
  • [Cites] FEBS Lett. 2004 Aug 13;572(1-3):65-8 [15304325.001]
  • [Cites] J Physiol. 2004 Sep 15;559(Pt 3):799-812 [15272030.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1389-95 [15475518.001]
  • [Cites] J Biol Chem. 1985 Mar 25;260(6):3440-50 [3838314.001]
  • [Cites] Am J Physiol. 1992 Aug;263(2 Pt 1):C348-56 [1514583.001]
  • [Cites] J Neurochem. 1993 Oct;61(4):1506-14 [8397296.001]
  • [Cites] J Gen Physiol. 1994 May;103(5):787-805 [7913485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13067 [7809171.001]
  • [Cites] Am J Physiol. 1996 Mar;270(3 Pt 1):C711-30 [8638650.001]
  • [Cites] Am J Physiol. 1996 Jun;270(6 Pt 1):C1703-8 [8764153.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12020-5 [8876255.001]
  • [Cites] Mol Biol Cell. 1996 Nov;7(11):1679-90 [8930892.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15735-40 [9861039.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7655-9 [16682648.001]
  • [Cites] Pflugers Arch. 2006 Jul;452(4):396-406 [16604368.001]
  • [Cites] IUBMB Life. 2006 Jul;58(7):409-19 [16801216.001]
  • [Cites] J Physiol. 2006 May 1;572(Pt 3):677-89 [16527858.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22992-3002 [16754672.001]
  • [Cites] Nat Med. 2006 Aug;12(8):950-4 [16862155.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Oct;291(4):C757-71 [16687471.001]
  • [Cites] Glia. 2006 Nov 15;54(7):758-73 [17006904.001]
  • [Cites] EMBO J. 2006 Nov 1;25(21):5071-82 [17036048.001]
  • [Cites] EMBO J. 2007 Feb 7;26(3):657-67 [17235286.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1068-77 [17148779.001]
  • [Cites] Mol Cells. 2007 Feb 28;23(1):11-6 [17464206.001]
  • [Cites] Glia. 2007 Jul;55(9):917-25 [17437307.001]
  • [Cites] Cell Mol Life Sci. 2007 Jun;64(12):1471-83 [17375261.001]
  • [Cites] J Neurosci. 2008 Jan 16;28(3):681-95 [18199768.001]
  • [Cites] J Neurosci. 2008 Feb 20;28(8):1804-15 [18287497.001]
  • [Cites] J Cell Physiol. 2008 Jul;216(1):14-28 [18300263.001]
  • [Cites] Cell Res. 2008 May;18(5):558-65 [18414449.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4702-11 [18448647.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jul;295(1):C231-41 [18495810.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Sep;295(3):C761-7 [18596212.001]
  • [Cites] Pharmacology. 2008;82(4):257-63 [18841035.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Dec;295(6):C1550-60 [18923056.001]
  • [Cites] Glia. 2009 Feb;57(3):258-69 [18837047.001]
  • [Cites] Physiol Rev. 2009 Jan;89(1):193-277 [19126758.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Feb;328(2):409-18 [19023039.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Feb 27;380(1):50-3 [19150332.001]
  • [Cites] J Physiol Sci. 2009 Jan;59(1):3-21 [19340557.001]
  • [Cites] J Physiol. 2009 May 15;587(Pt 10):2141-9 [19171657.001]
  • [Cites] J Physiol. 2009 May 15;587(Pt 10):2197-209 [19188250.001]
  • [Cites] J Neurosci. 2009 May 27;29(21):7092-7 [19474335.001]
  • [Cites] Annu Rev Biomed Eng. 2009;11:135-62 [19400711.001]
  • [Cites] J Biol Chem. 2009 Jul 31;284(31):20638-48 [19439413.001]
  • [Cites] Neuropharmacology. 2009 Sep;57(4):343-6 [19577581.001]
  • [Cites] FEBS J. 2009 Nov;276(21):6258-70 [19780818.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Nov;41(5):525-34 [19213873.001]
  • [Cites] Br J Pharmacol. 1999 Sep;128(1):35-40 [10498832.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Dec;311(3):1097-104 [15292461.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jan;288(1):C204-13 [15371260.001]
  • [Cites] J Neurochem. 2005 Mar;92(5):1033-43 [15715654.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Nov;315(2):755-63 [16051696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16466-71 [16254051.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):239-44 [16364313.001]
  • [Cites] Science. 2006 May 12;312(5775):924-7 [16690868.001]
  • (PMID = 19907018.001).
  • [ISSN] 1522-1563
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM036387; United States / NIGMS NIH HHS / GM / R01-GM36387; United States / NHLBI NIH HHS / HL / T32-HL07653; United States / NIGMS NIH HHS / GM / T32-GM07250; United States / NIGMS NIH HHS / GM / T32 GM007250
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anions; 0 / Chelating Agents; 0 / Hypertonic Solutions; 0 / Hypotonic Solutions; 0 / Ion Channels; 0 / Receptor, PAR-1; 0 / Tetanus Toxin; 139890-68-9 / 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; 1F7A44V6OU / Colforsin; 526U7A2651 / Egtazic Acid; 64657-18-7 / 1,9-dideoxyforskolin; 8L70Q75FXE / Adenosine Triphosphate; EC 3.4.21.5 / Thrombin; EC 3.6.5.2 / rho GTP-Binding Proteins; MM6384NG73 / Carbenoxolone; PO572Z7917 / Probenecid
  • [Other-IDs] NLM/ PMC2822496
  •  go-up   go-down


2. Takata K, Gasparetto EL, Leite Cda C, Lucato LT, Reed UC, Matushita H, Aguiar PH, Rosemberg S: [Subependymal giant cell astrocytoma in patients with tuberous sclerosis: magnetic resonance imaging findings in ten cases]. Arq Neuropsiquiatr; 2007 Jun;65(2A):313-6
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subependymal giant cell astrocytoma in patients with tuberous sclerosis: magnetic resonance imaging findings in ten cases].
  • [Transliterated title] Astrocitoma subependimário de células gigantes em pacientes com esclerose tuberosa: achados em ressonância magnética de dez casos.
  • OBJECTIVE: To report the magnetic resonance imaging (MRI) findings in 10 patients with subependimal giant cell astrocytoma (SGCA) and tuberous sclerosis (TS).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Ventricles / pathology. Tuberous Sclerosis / pathology


3. Hoyama E, Cruz AA, Colli BO, Matos JR, Chahud F: Isolated low grade pilocytic astrocytoma of the optic nerve in the elderly: case report. Arq Bras Oftalmol; 2008 Jan-Feb;71(1):97-100
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated low grade pilocytic astrocytoma of the optic nerve in the elderly: case report.
  • A 68-year-old man presented with a history of a right optic glioma.
  • At that time histology revealed that the tumor was an optic nerve glioma with a pilocytic pattern.
  • The tumor was excised by a combined neurosurgical and orbital approach.
  • Histology proved that the neoplasm was a low grade pilocytic astrocytoma of the optic nerve.
  • [MeSH-major] Astrocytoma / diagnosis. Optic Nerve Neoplasms / diagnosis
  • [MeSH-minor] Aged. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408847.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


Advertisement
4. Abate LE, Mukherjee P, Seyfried TN: Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma. J Neurochem; 2006 Sep;98(6):1973-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma.
  • Brain tumor growth and progression is dependent upon vascularity, and is associated with altered ganglioside composition and distribution.
  • In this study, we examined the influence of gangliosides on growth and vascularity in a malignant mouse astrocytoma, CT-2A.
  • Ganglioside distribution was altered in CT-2A tumor cells using an antisense construct to beta-1,4-N-acetylgalactosaminyltransferase (GalNAc-T), a key enzyme that uses the simple ganglioside GM3 as a substrate for the synthesis of the more complex gangliosides, GM2, GM1 and GD1a.
  • GalNAc-T gene expression was significantly lower in CT-2A cells stably transfected with the antisense GalNAc-T plasmid, pcDNA3.1/TNG (CT-2A/TNG) than in either non-transfected CT-2A or mock-transfected (CT-2A/V) control tumor cells.
  • GM3 was elevated from 16% to 58% of the total ganglioside distribution, whereas GM1 and GD1a were reduced from 17% and 49% to 10% and 17%, respectively, in CT-2A/TNG tumor cells.
  • In addition, the expression of VEGF, hypoxia-inducible factor 1alpha (HIF-1alpha) and neuropilin-1 (NP-1) was significantly lower in CT-2A/TNG tumor cells than in control CT-2A tumor cells.
  • These data suggest that gene-linked changes in ganglioside composition influence the growth and angiogenic properties of the CT-2A astrocytoma.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Gangliosides / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911584.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102135; United States / NICHD NIH HHS / HD / HD39722
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Oligonucleotides, Antisense; 0 / Vascular Endothelial Growth Factor A; 144713-63-3 / Neuropilin-1; EC 2.4.1.- / N-Acetylgalactosaminyltransferases; EC 2.4.1.41 / polypeptide N-acetylgalactosaminyltransferase
  •  go-up   go-down


5. Choi K, Ryu SW, Song S, Choi H, Kang SW, Choi C: Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ; 2010 May;17(5):833-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family of cytokines, causes apoptosis by caspase activation in various cell types, particularly in transformed cells.
  • We report here a new signal transduction pathway involving protein kinase Cdelta (PKCdelta), NADPH oxidase 4 (NOX4) and reactive oxygen species (ROS), that inhibits caspase-dependent cell death induced by TRAIL ligation in human malignant astrocytoma cells.
  • [MeSH-major] Apoptosis / physiology. Astrocytoma / metabolism. Caspase 3 / metabolism. Reactive Oxygen Species / metabolism. TNF-Related Apoptosis-Inducing Ligand / metabolism
  • [MeSH-minor] Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Humans. Immunoblotting. NADPH Oxidase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876066.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.6.3.- / NOX4 protein, human; EC 1.6.3.1 / NADPH Oxidase; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


6. Jiang L, Saetre P, Jazin E, Carlström EL: Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells. BMC Pharmacol; 2009;9:6
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells.
  • Disturbed QKI mRNA expression is observed in the prefrontal cortex of patients, and some of these changes correlate to treatment with antipsychotic drugs.To test if low doses of antipsychotic drugs can modify QKI mRNA expression, human astrocytoma (U343) and oligodendroglioma (HOG) cell lines were treated with five different antipsychotic drugs including Haloperidol, Aripiprazole, Clozapine, Olanzapine and Risperidone.
  • [MeSH-minor] Alternative Splicing. Antipsychotic Agents / pharmacology. Aripiprazole. Astrocytoma / genetics. Astrocytoma / pathology. Benzodiazepines / pharmacology. Cell Line, Tumor. Clozapine / pharmacology. Dose-Response Relationship, Drug. Humans. Piperazines / pharmacology. Quinolones / pharmacology. Receptors, Dopamine D2 / genetics. Reverse Transcriptase Polymerase Chain Reaction. Risperidone / pharmacology. Time Factors

  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. Olanzapine .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacology (Berl). 2000 Jan;148(1):83-9 [10663421.001]
  • [Cites] J Neurol Sci. 2008 Apr 15;267(1-2):3-16 [17935736.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):96-105 [11389481.001]
  • [Cites] Lancet. 2003 Sep 6;362(9386):798-805 [13678875.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):945-9 [14499311.001]
  • [Cites] J Neurosci Res. 1998 Feb 15;51(4):417-22 [9514195.001]
  • [Cites] Pharmacopsychiatry. 2004 Nov;37(6):243-65 [15551191.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2006 Jan 5;141B(1):84-90 [16342280.001]
  • [Cites] Neuron. 2006 Mar 16;49(6):823-32 [16543131.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 9;103(19):7482-7 [16641098.001]
  • [Cites] FASEB J. 2006 Jun;20(8):1263-5 [16636101.001]
  • [Cites] Am J Psychiatry. 2007 Jan;164(1):175 [17202571.001]
  • [Cites] J Neurosci Res. 2007 Mar;85(4):757-65 [17177202.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23553-60 [17575274.001]
  • [Cites] Genome Res. 2000 Aug;10(8):1219-29 [10958640.001]
  • (PMID = 19335891.001).
  • [ISSN] 1471-2210
  • [Journal-full-title] BMC pharmacology
  • [ISO-abbreviation] BMC Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Piperazines; 0 / QKI protein, human; 0 / Quinolones; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Receptors, Dopamine D2; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine; 82VFR53I78 / Aripiprazole; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone
  • [Other-IDs] NLM/ PMC2676266
  •  go-up   go-down


7. Schittenhelm J, Psaras T: Glioblastoma with granular cell astrocytoma features: a case report and literature review. Clin Neuropathol; 2010 Sep-Oct;29(5):323-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma with granular cell astrocytoma features: a case report and literature review.
  • We present the case of a 69-year old patient with a contrast enhancing, partially cystic lesion of the right temporal lobe, involving the ventricle and extending into the occipital lobe.
  • The resected tumor showed histological features of a glioblastoma with granular cell astrocytoma features, lacking amplification of the EGFR gene region and IDH1R132H mutation.
  • Literature review of 59 cases showed a 12-month overall survival of 11.7% for high-grade and 40% for low-grade granular cell astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860896.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


8. Vassilyadi M, Michaud J: Hydrocephalus as the initial presentation of a spinal cord astrocytoma associated with leptomeningeal spread. Pediatr Neurosurg; 2005 Jan-Feb;41(1):29-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrocephalus as the initial presentation of a spinal cord astrocytoma associated with leptomeningeal spread.
  • The enhancement was initially thought to be the result of a partially treated meningitis (child was previously on oral antibiotics for a presumed mycoplasma pneumonia).
  • The lesion was subtotally resected (70%) and diagnosed as an astrocytoma (mostly Kernohan grade 2 but with areas of grade 3).
  • Chemotherapy was administered and follow-up spine MRI at 2 months did not reveal any residual tumor, however, the leptomeningeal enhancement persisted.
  • This case illustrates how a spinal cord astrocytoma can metastasize via spinocranial dispersion and present early with hydrocephalus rather than myelopathy.
  • [MeSH-major] Astrocytoma / pathology. Hydrocephalus / etiology. Meningeal Neoplasms / complications. Meningeal Neoplasms / secondary. Neoplastic Cells, Circulating. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15886510.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Arai K, Sato N, Aoki J, Yagi A, Taketomi-Takahashi A, Morita H, Koyama Y, Oba H, Ishiuchi S, Saito N, Endo K: MR signal of the solid portion of pilocytic astrocytoma on T2-weighted images: is it useful for differentiation from medulloblastoma? Neuroradiology; 2006 Apr;48(4):233-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR signal of the solid portion of pilocytic astrocytoma on T2-weighted images: is it useful for differentiation from medulloblastoma?
  • BACKGROUND AND PURPOSE: Although imaging features of cerebellar pilocytic astrocytoma and medulloblastoma have been described in many texts, original comparisons of magnetic resonance intensity between these two tumours are limited.
  • METHODS: MR images of ten cerebellar pilocytic astrocytomas and ten medulloblastomas were reviewed.
  • RESULTS: On T2-weighted images, the signal intensity of the solid portion was equal to that of cerebrospinal fluid (CSF) in 50% of pilocytic astrocytomas.
  • On T1-weighted images, the signal intensity varied widely in pilocytic astrocytomas; however, all medulloblastomas were iso- or hypointense to grey matter.
  • CONCLUSION: A signal intensity of the solid portion isointense to CSF on T2-weighted images was characteristic of cerebellar pilocytic astrocytomas; this was not observed in medulloblastomas.
  • Attention to T2-weighted imaging of the solid portions of a tumour is easy and helpful in differentiating between cerebellar pilocytic astrocytoma and medulloblastoma.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Medulloblastoma / diagnosis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550430.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Chen JH, Tsou TC, Chiu IM, Chou CC: Proliferation inhibition, DNA damage, and cell-cycle arrest of human astrocytoma cells after acrylamide exposure. Chem Res Toxicol; 2010 Sep 20;23(9):1449-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation inhibition, DNA damage, and cell-cycle arrest of human astrocytoma cells after acrylamide exposure.
  • This study aimed to determine the effects of ACR-induced DNA damage on cell cycle regulation in human astrocytoma cell lines.
  • Expression of DNA damage-associated/checkpoint-related signaling molecules, including phosphorylated-p53 (pp53), p53, p21, p27, Cdk2, and cyclin D(1), in three human astrocytoma cell lines (U-1240 MG, U-251 MG, and U-87 MG) was also analyzed by immunoblotting.
  • This in vitro study clearly demonstrates the critical role of ATM/ATR in the signaling of ACR-induced cell-cycle arrest in astrocytoma cells.
  • [MeSH-minor] Astrocytoma. Ataxia Telangiectasia Mutated Proteins. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Comet Assay. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. DNA-Binding Proteins / metabolism. G0 Phase / drug effects. G1 Phase / drug effects. Humans. Protein-Serine-Threonine Kinases / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism

  • Hazardous Substances Data Bank. ACRYLAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734998.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 20R035KLCI / Acrylamide; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


11. Xiangsong Z, Weian C: Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol; 2007 May;82(3):305-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET.
  • Differentiation of posttherapy radiation necrosis from recurrent brain tumor remains a challenging diagnostic problem.
  • The present study assessed the role of (13)N-NH(3) PET in differentiating recurrent cerebral astrocytoma from radiation necrosis.
  • METHODS: Seven patients, who were previously treated with conventional external-beam radiation therapy after surgical resection for cerebral astrocytomas, and showed the enhancing brain lesions on T1-weighted gadiolinium-enhanced MR studies performed in 6 months or above after the radiotherapies, were examined prospectively with (13)N-NH(3) and FDG PET.
  • Five lesions with tumor recurrence and two with radiation necrosis were histologically verified by either surgical resection or stereotactic biopsy.
  • The lesions with recurrent tumor showed moderately to markedly increased (13)N-NH(3) uptake (grade = 4-5).
  • The other lesion with anaplastic astrocytoma showed moderately increased (13)N-NH(3) uptake (grade = 4), but slightly less FDG uptake than surrounding area (grade = 2).
  • CONCLUSIONS: The recurrent astrocytomas showed increased (13)N-NH(3) uptake, and the radiation necrosis showed absent or less (13)N-NH(3) uptake, and (13)N-NH(3) seem superior to (18)F-FDG for this purpose, suggesting that (13)N-NH(3) is a promising tracer for separating radiation necrosis from astrocytoma recurrence.
  • [MeSH-major] Astrocytoma / pathology. Brain Diseases / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis. Nitrogen Radioisotopes

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17120157.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nitrogen Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Holden LJ, Coleman MD: Assessment of the astrogliotic responses of three human astrocytoma cell lines to ethanol, trimethyltin chloride and acrylamide. Toxicology; 2007 Nov 20;241(1-2):75-83
Hazardous Substances Data Bank. ACRYLAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the astrogliotic responses of three human astrocytoma cell lines to ethanol, trimethyltin chloride and acrylamide.
  • The astrogliotic responses of the CCF-STTG1, U251-MG, and U373-MG human astrocytoma lines were determined after exposure to ethanol, trimethyltin chloride (TMTC), and acrylamide over 4, 16, and 24h.
  • Ethanol treatment over 24h, but not at 4 and 16h, resulted in significant increases in GFAP in all three glioma lines at sub-cytotoxic levels; the GFAP responses in the CCF-STTG1 line were the most sensitive, as concentrations of 0.1 and 1mM led to increases in GFAP expression compared with control of 56.8+/-15.7 and 58.9+/-11.5%, respectively (P<0.05).
  • This study underlines the significance of period of exposure, as well as toxin concentration in astrocytoma cellular response to toxic pressure.
  • [MeSH-major] Acrylamide / toxicity. Astrocytoma / pathology. Brain Neoplasms / pathology. Central Nervous System Depressants / toxicity. Ethanol / toxicity. Gliosis / pathology. Trimethyltin Compounds / toxicity
  • [MeSH-minor] Cell Count. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Mitochondria / drug effects. Mitochondria / enzymology. Oxidoreductases / metabolism. Tetrazolium Salts. Thiazoles

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875352.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Glial Fibrillary Acidic Protein; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Trimethyltin Compounds; 20R035KLCI / Acrylamide; 298-93-1 / thiazolyl blue; 3K9958V90M / Ethanol; EC 1.- / Oxidoreductases
  •  go-up   go-down


13. Klase D, Gottschalk S, Reusche E, Hagel C, Goebel E, Tronnier V, Giese A: Lumbosacral glioblastoma and leptomeningeal gliomatosis complicating the course of a cervicothoracic astrocytoma WHO grade II. Childs Nerv Syst; 2007 Aug;23(8):907-12
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lumbosacral glioblastoma and leptomeningeal gliomatosis complicating the course of a cervicothoracic astrocytoma WHO grade II.
  • CASE REPORT: The reported female patient underwent sub-total resection of an intra-medullary cervicothoracic astrocytoma classified as WHO grade II in 1984 at the age of 18 months and received local irradiation.
  • The patient was implanted with a ventriculoperitoneal shunt for a pseudo-tumour cerebri producing papilloedema, which eventually lead to amaurosis.
  • DISCUSSION AND CONCLUSION: Anaplastic progression and dissemination of spinal astrocytomas even two decades after initial diagnosis and treatment are rare.
  • [MeSH-major] Astrocytoma / complications. Glioblastoma / complications. Meningeal Neoplasms / complications. Spinal Cord Neoplasms / complications
  • [MeSH-minor] Adult. Back Pain / etiology. Blindness / complications. Blindness / pathology. Cerebrospinal Fluid Shunts. Eye / pathology. Fatal Outcome. Female. Humans. Lordosis / etiology. Magnetic Resonance Imaging. Peripheral Nervous System Diseases / complications. Pituitary Gland / pathology. Pseudotumor Cerebri / pathology. Pseudotumor Cerebri / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440736.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Yoshida T, Sasayama H, Nakagawa M: The process of inducing GFAP aggregates in astrocytoma-derived cells is different between R239C and R416W mutant GFAP. A time-lapse recording study. Neurosci Lett; 2009 Jul 10;458(1):11-4
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The process of inducing GFAP aggregates in astrocytoma-derived cells is different between R239C and R416W mutant GFAP. A time-lapse recording study.
  • Alexander disease (ALX) is a rare neurodegenerative disease caused by the gene mutations encoding glial fibrillary acidic protein (GFAP).
  • R239C and R416W GFAP mutations located in the rod domain and tail domain, respectively, were transfected into astrocytoma-derived cells, and their real-time dynamics were observed using time-lapse recording.
  • [MeSH-major] Amino Acids / genetics. Astrocytoma / metabolism. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Point Mutation / physiology
  • [MeSH-minor] Arginine / genetics. Cell Line, Tumor. Cysteine / genetics. Green Fluorescent Proteins / genetics. Humans. Microscopy, Confocal / methods. Protein Transport / genetics. Time Factors. Transfection / methods. Tryptophan / genetics

  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379794.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Glial Fibrillary Acidic Protein; 147336-22-9 / Green Fluorescent Proteins; 8DUH1N11BX / Tryptophan; 94ZLA3W45F / Arginine; K848JZ4886 / Cysteine
  •  go-up   go-down


15. Crabtree KL, Arnold PM: Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously. Pediatr Neurosurg; 2010;46(1):66-70
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously.
  • Pilocytic astrocytoma (PA) is a slow-growing, well-circumscribed grade I glioma generally considered benign, with a low recurrence rate and an excellent prognosis following complete surgical resection.
  • PA is the most common central nervous system glioma in the pediatric population and is rare in adults.
  • To our knowledge, this is the longest time reported from initial tumor resection of leptomeningeal dissemination to the distal spinal cord.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasm Seeding. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516744.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Tanizaki Y, Sato Y, Oka H, Utsuki S, Kondo K, Miyajima Y, Nagashio R, Fujii K: Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma. Pathol Int; 2006 Sep;56(9):510-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma.
  • It has been reported that tumor infiltration is correlated with the expression of autocrine motility factor (AMF) and its receptor 78 kDa glycoprotein (gp78).
  • The purpose of the present study was to detect AMF and gp78 mRNA expression levels and their localization in high-grade astrocytomas (glioblastoma and anaplastic astrocytoma) and to determine whether AMF and gp78 are important prognostic factors.
  • A total of 32 formalin-fixed and paraffin-embedded glioblastomas and 23 formalin-fixed and paraffin-embedded anaplastic astrocytomas was used.
  • The expression of AMF mRNA was detected in 27 of 32 glioblastomas (84.4%) and 11 of 23 anaplastic astrocytomas (47.8%).
  • The positivity of AMF mRNA was significantly higher in glioblastomas than in anaplastic astrocytomas (P = 0.0094), but gp78 mRNA was detected in most cases and no statistical significance was observed.
  • In anaplastic astrocytomas, the overall survival of patients with AMF expression was also significantly shorter than in patients without AMF expression (P = 0.0058).
  • This study demonstrated that AMF is a poor prognostic factor in high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Glucose-6-Phosphate Isomerase / biosynthesis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930331.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Cytokine; EC 5.3.1.9 / Glucose-6-Phosphate Isomerase; EC 6.3.2.19 / AMFR protein, human; EC 6.3.2.19 / Receptors, Autocrine Motility Factor; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


17. Daszkiewicz P, Maryniak A, Roszkowski M, Barszcz S: Long-term functional outcome of surgical treatment of juvenile pilocytic astrocytoma of the cerebellum in children. Childs Nerv Syst; 2009 Jul;25(7):855-60
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term functional outcome of surgical treatment of juvenile pilocytic astrocytoma of the cerebellum in children.
  • PURPOSE: Increasing incidence of pediatric brain tumors and improving survival rates encouraged us to assess long-term functional outcome of patients with cerebellar juvenile pilocytic astrocytoma (JPA).
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cerebellum / surgery. Child. Child, Preschool. Education. Female. Follow-Up Studies. Humans. Infant. Male. Mood Disorders / etiology. Nervous System Diseases / etiology. Parents / psychology. Patient Satisfaction. Surveys and Questionnaires. Survival. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418058.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Bartik P, Maglott A, Entlicher G, Vestweber D, Takeda K, Martin S, Dontenwill M: Detection of a hypersialylated beta1 integrin endogenously expressed in the human astrocytoma cell line A172. Int J Oncol; 2008 May;32(5):1021-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of a hypersialylated beta1 integrin endogenously expressed in the human astrocytoma cell line A172.
  • Gliomas are the most common deadly brain tumors.
  • As a potential new target, alpha5beta1 was investigated here in two human astrocytoma cell lines, A172 and U87MG.
  • Overexpression of the beta1 integrin subunit in A172 cells not only increased the hypersialylated form but also led to the appearance of a non-hypersialylated beta1 form also addressed to the cell surface.
  • [MeSH-major] Antigens, CD29 / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Protein Processing, Post-Translational. Sialic Acids / metabolism
  • [MeSH-minor] Cell Adhesion. Cell Line, Tumor. Cell Membrane / metabolism. Cell Proliferation. Dimerization. Fibronectins / metabolism. Glycosylation. Humans. Integrin alpha5 / metabolism. Integrin alpha5beta1 / antagonists & inhibitors. Integrin alpha5beta1 / metabolism. Propionates / pharmacology. Pyridines / pharmacology. Spiro Compounds / pharmacology. Transfection. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425328.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Fibronectins; 0 / Integrin alpha5; 0 / Integrin alpha5beta1; 0 / Propionates; 0 / Pyridines; 0 / SJ749; 0 / Sialic Acids; 0 / Spiro Compounds
  •  go-up   go-down


19. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer; 2009 Jan;45(1):146-53
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
  • AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.
  • RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.
  • Among 10 (26%) patients with a hypermethylated MGMT promoter, none experienced disease progression within the first two treatment cycles compared with 12 of 28 (43%) patients with an unmethylated promoter (p=0.016).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Methylation. Female. Glioblastoma / drug therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945611.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


20. Yoshida H, Imaizumi T, Lee SJ, Tanji K, Sakaki H, Matsumiya T, Ishikawa A, Taima K, Yuzawa E, Mori F, Wakabayashi K, Kimura H, Satoh K: Retinoic acid-inducible gene-I mediates RANTES/CCL5 expression in U373MG human astrocytoma cells stimulated with double-stranded RNA. Neurosci Res; 2007 Jun;58(2):199-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid-inducible gene-I mediates RANTES/CCL5 expression in U373MG human astrocytoma cells stimulated with double-stranded RNA.
  • In the present study, we demonstrated that poly IC enhances the expression of RIG-I in U373MG human astrocytoma cells.
  • [MeSH-major] Astrocytoma / metabolism. Chemokine CCL5 / metabolism. Gene Expression / drug effects. RNA, Double-Stranded / pharmacology. Transcription Factors / metabolism
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Interactions. Enzyme Inhibitors / pharmacology. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Neoplastic / drug effects. Glial Fibrillary Acidic Protein / metabolism. Humans. Imidazoles / pharmacology. Interferon Inducers / pharmacology. Poly I-C / pharmacology. Pyridines / pharmacology. Time Factors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395328.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Chemokine CCL5; 0 / Enzyme Inhibitors; 0 / Glial Fibrillary Acidic Protein; 0 / Imidazoles; 0 / Interferon Inducers; 0 / Pyridines; 0 / RAI1 protein, human; 0 / RNA, Double-Stranded; 0 / SB 203580; 0 / Transcription Factors; 24939-03-5 / Poly I-C
  •  go-up   go-down


21. Balestri F, Giannecchini M, Sgarrella F, Carta MC, Tozzi MG, Camici M: Purine and pyrimidine nucleosides preserve human astrocytoma cell adenylate energy charge under ischemic conditions. Neurochem Int; 2007 Feb;50(3):517-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purine and pyrimidine nucleosides preserve human astrocytoma cell adenylate energy charge under ischemic conditions.
  • In this paper, we report that human astrocytoma cells (ADF) undergoing ischemic conditions may use both purine and pyrimidine nucleosides as energy source to slow down cellular damage.
  • [MeSH-major] Adenine Nucleotides / metabolism. Astrocytoma / metabolism. Brain Ischemia / metabolism. Purine Nucleosides / physiology. Pyrimidine Nucleosides / physiology
  • [MeSH-minor] Cell Line, Tumor. Culture Media. Humans. Oligomycins / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126452.001).
  • [ISSN] 0197-0186
  • [Journal-full-title] Neurochemistry international
  • [ISO-abbreviation] Neurochem. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Culture Media; 0 / Oligomycins; 0 / Purine Nucleosides; 0 / Pyrimidine Nucleosides
  •  go-up   go-down


22. Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC: Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):380-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
  • PURPOSE: To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma.
  • The primary study endpoint was the 23-month (700-day) survival, the median survival of patients with anaplastic astrocytoma in a previous North Central Cancer Treatment Group trial.
  • CONCLUSION: Our results have demonstrated that pre-RT chemotherapy with this regimen is insufficiently active in patients with anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy


23. de Carvalho Neto A, Gasparetto EL, Bruck I: Subependymal giant cell astrocytoma with high choline/creatine ratio on proton MR spectroscopy. Arq Neuropsiquiatr; 2006 Sep;64(3B):877-80
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma with high choline/creatine ratio on proton MR spectroscopy.
  • OBJECTIVE: To report a case of subependymal giant cell astrocytoma (SEGA) in a patient with tuberous sclerosis, emphasizing the proton MR spectroscopy (MRS) findings.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Choline / analysis. Creatine / analysis. Tuberous Sclerosis / complications
  • [MeSH-minor] Biomarkers, Tumor / analysis. Child, Preschool. Humans. Magnetic Resonance Spectroscopy. Male


24. Aarsen FK, Paquier PF, Arts WF, Van Veelen ML, Michiels E, Lequin M, Catsman-Berrevoets CE: Cognitive deficits and predictors 3 years after diagnosis of a pilocytic astrocytoma in childhood. J Clin Oncol; 2009 Jul 20;27(21):3526-32
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive deficits and predictors 3 years after diagnosis of a pilocytic astrocytoma in childhood.
  • PURPOSE To prospectively study cognitive deficits and predictors 3 years after diagnosis in a large series of pediatric patients treated for pilocytic astrocytoma (PA).
  • Included predictors were sex, age, relapse, diagnosis-assessment interval, hydrocephalus, kind of treatment, and tumor variables.
  • Verbal intelligence and verbal memory problems occurred in the brainstem tumor group.
  • The supratentorial hemispheric tumor group had additional problems with selective attention and executive functioning, and the supratentorial midline tumor group displayed no extra impairments.
  • More specifically, the dorsal supratentorial midline tumor group displayed problems with language and verbal memory.
  • Predictors for lower cognitive functioning were hydrocephalus, radiotherapy, residual tumor size, and age; predictors for better functioning were chemotherapy or treatment of hydrocephalus.
  • Adequate treatment of hydrocephalus is important for a more favorable long-term cognitive outcome.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Cerebellar Neoplasms / complications. Cognition Disorders / etiology. Hydrocephalus / etiology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Wierzba-Bobrowicz T, Lewandowska E, Matyja E, Dziduszko J, Koszewski W, Stepień T, Błazejewska-Hyzorek B: Granular cell astrocytoma. A case report with immunohistochemical and ultrastructural characterization. Folia Neuropathol; 2008;46(4):286-93
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell astrocytoma. A case report with immunohistochemical and ultrastructural characterization.
  • Granular cell astrocytoma (GCA) is an uncommon type of granular cell tumours (GCTs) in the central nervous system.
  • We report a case of cerebral GCA in a 59-year-old man who suffered from diabetes and Addison-Biermer disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169970.001).
  • [ISSN] 1641-4640
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


26. Nishibayashi H, Matsuda Y, Uematsu Y, Nakao N, Terada T, Itakura T: [A case of high grade astrocytoma arising in the hand area of precentral gyrus]. No To Shinkei; 2005 Jun;57(6):517-22
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of high grade astrocytoma arising in the hand area of precentral gyrus].
  • Histological examination revealed an high grade astrocytoma with high MlIB-1 index over 30%.
  • The progressive symptoms were due to highly infiltrative and proliferative nature of the tumor arising in the focal hand area of the primary motor cortex, according to the homunculus.
  • We discuss herein the neuroimagings of the case that was considered to be in the initial stage of a malignant tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspartic Acid / analogs & derivatives. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Motor Cortex / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026048.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 30KYC7MIAI / Aspartic Acid; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 997-55-7 / N-acetylaspartate; K2I13DR72L / Gadolinium DTPA; RYH2T97J77 / ranimustine
  •  go-up   go-down


27. Mahzouni P, Mohammadizadeh F, Mougouei K, Moghaddam NA, Chehrei A, Mesbah A: Determining the relationship between "microvessel density" and different grades of astrocytoma based on immunohistochemistry for "factor VIII-related antigen" (von Willebrand factor) expression in tumor microvessels. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):605-10
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the relationship between "microvessel density" and different grades of astrocytoma based on immunohistochemistry for "factor VIII-related antigen" (von Willebrand factor) expression in tumor microvessels.
  • BACKGROUND: Astrocytic brain tumors are the most common primary central nervous system tumors, which are classified into four grades.
  • One of the most important pathologic criteria for the diagnosis of higher-grade astrocytomas (especially glioblastoma multiforme) is microvessel proliferation, particularly in the form of glomeruloid complex.
  • Because tumor angiogenesis is a necessary factor for growth and invasiveness of malignancies, microvessel density (MVD) and intensity of angiogenesis may be used to determine the grade of astrocytomas and plan therapy accordingly.
  • We have planned this study to evaluate the relationship between vwf expression in microvessels and different grades of astrocytoma.
  • MATERIALS AND METHODS: Sixty-four formalin-fixed and paraffin-embedded blocks of surgical specimens with diagnosis of astrocytoma (grades I to IV, each of them 16 blocks) were selected in a simple-nonrandom sampling.
  • Scores 0 and 1 of microvessel staining intensity were not observed in any grades studied, but severe staining intensity (score 3) was observed in 18.8%, 37.5%, 56.3%, and 87.5% of grades I, II, III, and IV astrocytomas, respectively.
  • "Vwf vessel index" (MVD staining intensity of microvessels) was 23.84, 25.62, 31.62, and 62.43 in grades I, II, III, and IV astrocytomas, respectively.
  • CONCLUSION: We found a significant relationship between staining intensity of vwf in microvessels and different grades of astrocytomas.
  • The intensity of microvessel stain increases in parallel with increasing tumor grade.
  • [MeSH-major] Astrocytoma / pathology. Microvessels / pathology. Neovascularization, Pathologic. Severity of Illness Index. von Willebrand Factor / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045378.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / von Willebrand Factor; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


28. Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW, Yang BH, Yen SH, Huang MC, Liao SQ, Yeh SH: PET imaging of brain astrocytoma with 1-11C-acetate. Eur J Nucl Med Mol Imaging; 2006 Apr;33(4):420-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging of brain astrocytoma with 1-11C-acetate.
  • PURPOSE: The purpose of this study was to assess the use of 1-(11)C-acetate (ACE) as a metabolic tracer for the detection and characterisation of astrocytomas.
  • METHODS: Positron emission tomography (PET) studies with ACE and 2-(18)F-fluoro-2-deoxy-D-glucose (FDG) were performed sequentially in 26 patients with primary astrocytomas.
  • RESULTS: There were 85% of astrocytomas with ++ ACE uptake, 15% with + ACE uptake and none with - ACE uptake.
  • Only 19% of astrocytomas had ++ FDG uptake.
  • Thirty-seven percent of high-grade astrocytomas had + FDG uptake and 37% had - FDG uptake.
  • The sensitivity and specificity of the FDG T/C ratio in discriminating high-grade from low-grade astrocytomas were 79% and 100%, respectively, at the cutoff value of 0.75.
  • FDG was better than ACE in discriminating high-grade from low-grade astrocytomas.
  • CONCLUSION: ACE appears to be a promising tracer for use in the detection of primary astrocytomas, but is of limited value in the differentiation of high- and low-grade astrocytomas.
  • ACE is complementary to FDG for the diagnosis and characterisation of astrocytoma.
  • [MeSH-major] Acetates. Astrocytoma / radionuclide imaging. Brain Neoplasms / radionuclide imaging. Carbon. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CARBON .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404596.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acetates; 0 / Radiopharmaceuticals; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


29. Abel TJ, Chowdhary A, Thapa M, Rutledge JC, Geyer JR, Ojemann J, Avellino AM: Spinal cord pilocytic astrocytoma with leptomeningeal dissemination to the brain. Case report and review of the literature. J Neurosurg; 2006 Dec;105(6 Suppl):508-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord pilocytic astrocytoma with leptomeningeal dissemination to the brain. Case report and review of the literature.
  • Leptomeningeal dissemination of low-grade spinal cord gliomas is an uncommon event.
  • The authors report a unique case of leptomeningeal dissemination of a spinal cord pilocytic astrocytoma (PCA) to the intracranial cerebral subarachnoid spaces in a child.
  • An intradural intramedullary spinal cord tumor was identified, and the lesion was subtotally resected and diagnosed by the pathology department to be a PCA.
  • Subsequently, the patient had recurrences of the intradural intramedullary tumor at 6 months and 2 years after his original presentation.
  • He underwent a repeated resection of the recurrent tumor and fenestration of an associated syrinx on both occasions.
  • The pathological characteristics of the reresected tumor remained consistent with those of a PCA.
  • Postoperative imaging after his last surgery revealed diffuse intracranial leptomeningeal dissemination into the cisternal space surrounding the midbrain, the suprasellar region, and the internal auditory canal, as well as nodular subarachnoid disease in the upper cervical region.
  • The patient then underwent chemotherapy, and total spine magnetic resonance (MR) imaging 2 months later demonstrated stability in the size of the spinal cord tumor and a decrease in the associated syrinx.
  • However, an MR image of the head demonstrated two new areas of supratentorial subarachnoid leptomeningeal spread of the primary spinal cord tumor at the 2-month follow-up examination.
  • At the 6-month follow-up examination, MR imaging of the head and spine demonstrated stable metastatic disease.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery


30. Lai JC, Ananthakrishnan G, Jandhyam S, Dukhande VV, Bhushan A, Gokhale M, Daniels CK, Leung SW: Treatment of human astrocytoma U87 cells with silicon dioxide nanoparticles lowers their survival and alters their expression of mitochondrial and cell signaling proteins. Int J Nanomedicine; 2010;5:715-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of human astrocytoma U87 cells with silicon dioxide nanoparticles lowers their survival and alters their expression of mitochondrial and cell signaling proteins.
  • To investigate this hypothesis, we determined the activities of the key mitochondrial enzymes, citrate synthase and malate dehydrogenase, in astrocytoma U87 cells treated with silicon dioxide nanoparticles.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Nanoparticles / toxicity. Neurons / drug effects. Silicon Dioxide / toxicity
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. DNA, Mitochondrial / genetics. Humans. Intracellular Signaling Peptides and Proteins / drug effects. Intracellular Signaling Peptides and Proteins / metabolism. Mitochondrial Proteins / drug effects. Mitochondrial Proteins / genetics. Mitochondrial Proteins / metabolism. Nanomedicine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Sci. 2007 May;97(1):163-80 [17301066.001]
  • [Cites] J Nutr Health Aging. 2007 Mar-Apr;11(2):94-7 [17435951.001]
  • [Cites] J Neuroimmune Pharmacol. 2008 Dec;3(4):286-95 [18830698.001]
  • [Cites] Int J Nanomedicine. 2008;3(4):533-45 [19337421.001]
  • [Cites] Small. 2009 Apr;5(7):846-53 [19288475.001]
  • [Cites] Acta Neurochir Suppl. 2010;106:359-64 [19812977.001]
  • [Cites] Acta Neuropathol. 2010 Jan;119(1):7-35 [20012068.001]
  • [Cites] Neurochem Res. 2007 Nov;32(11):1906-18 [17562167.001]
  • [Cites] Int Rev Neurobiol. 2002;53:25-56 [12512336.001]
  • [Cites] Neurochem Res. 2004 Apr;29(4):709-17 [15098932.001]
  • [Cites] Acta Neuropathol. 1983;59(1):31-40 [6301202.001]
  • [Cites] Lancet. 1986 Feb 15;1(8477):354-7 [2868298.001]
  • [Cites] Gerontology. 1995;41 Suppl 2:131-44 [8821327.001]
  • [Cites] Glia. 2005 Jun;50(4):351-61 [15846800.001]
  • [Cites] Cell Mol Neurobiol. 2005 Feb;25(1):25-39 [15962507.001]
  • [Cites] Drug Dev Ind Pharm. 2005 Aug;31(7):687-96 [16207616.001]
  • [Cites] Toxicol Sci. 2006 Jan;89(1):338-47 [16237191.001]
  • [Cites] Neurochem Res. 2006 Oct;31(10):1211-8 [17043766.001]
  • [Cites] Neurochem Res. 2006 Nov;31(11):1349-57 [17053969.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Dec 15;217(3):252-9 [17112558.001]
  • [Cites] Water Sci Technol. 2006;54(11-12):327-34 [17302336.001]
  • [Cites] Commun Agric Appl Biol Sci. 2006;71(2 Pt A):171-8 [17390789.001]
  • [ErratumIn] Int J Nanomedicine. 2011;6:33
  • (PMID = 21042417.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 7631-86-9 / Silicon Dioxide
  • [Other-IDs] NLM/ PMC2962267
  • [Keywords] NOTNLM ; cell signaling / cytotoxicity / extracellular signaling regulated kinase / mitochondrial enzyme / neural cells / silicon dioxide nanoparticles
  •  go-up   go-down


31. Nakao K, Shirakawa H, Sugishita A, Matsutani I, Niidome T, Nakagawa T, Kaneko S: Ca2+ mobilization mediated by transient receptor potential canonical 3 is associated with thrombin-induced morphological changes in 1321N1 human astrocytoma cells. J Neurosci Res; 2008 Sep;86(12):2722-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ca2+ mobilization mediated by transient receptor potential canonical 3 is associated with thrombin-induced morphological changes in 1321N1 human astrocytoma cells.
  • In the present study we revealed a novel function of astrocytic Ca(2+) dynamics through investigation of thrombin-induced unique Ca(2+) entry.
  • Using 1321N1 human astrocytoma cells, which have been shown to be a good model for detecting morphological dynamics, we observed rapid retraction of bipolar protrusions that were reversibly evoked by 0.03-3 U/mL thrombin.
  • Morphological changes were predominantly dependent on a specific thrombin receptor subtype, proteinase-activated receptor 1 (PAR-1).
  • These results suggest a novel function of astrocytic Ca(2+) dynamics, including Ca(2+) entry, in the pathophysiological effects of PAR-1-mediated astrocytic activation.
  • TRPC3 forms a functional Ca(2+) channel and might modulate astrocytic activation in response to brain hemorrhaging.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Calcium / metabolism. TRPC Cation Channels / physiology. Thrombin / physiology
  • [MeSH-minor] Calcium Signaling / physiology. Humans. Receptor, PAR-1 / genetics. Receptor, PAR-1 / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18478545.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, PAR-1; 0 / TRPC Cation Channels; 0 / TRPC3 cation channel; EC 3.4.21.5 / Thrombin; SY7Q814VUP / Calcium
  •  go-up   go-down


32. Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Agúndez JA, García-Martín E: Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol; 2010;10:71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.
  • Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the putative association between common nonsynonymous PON1 polymorphisms and the risk of developing astrocytoma and meningioma.
  • METHODS: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662.
  • RESULTS: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1 Q192R did not differ significantly between patients with astrocytoma and meningioma and controls.
  • The minor allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and control individuals, respectively.
  • Haplotype association analyses did not identify any significant association with the risk of developing astrocytoma or meningioma.
  • CONCLUSIONS: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing astrocytoma and meningioma.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single Nucleotide. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):341-9 [9712341.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 1;56(5):547-51 [9783722.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Liver Int. 2005 Oct;25(5):935-9 [16162149.001]
  • [Cites] Toxicology. 2005 Nov 15;215(3):182-90 [16102884.001]
  • [Cites] Occup Environ Med. 2005 Nov;62(11):786-92 [16234405.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):615-20 [16489678.001]
  • [Cites] Acta Neurol Scand. 2006 May;113(5):322-6 [16629768.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1513-6 [16685388.001]
  • [Cites] Pharmacogenomics. 2006 Jul;7(5):711-8 [16886896.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Drug Metab Dispos. 2007 Feb;35(2):315-20 [17132760.001]
  • [Cites] Occup Environ Med. 2007 Aug;64(8):509-14 [17537748.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jan;18(1):37-43 [18216720.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):976-85 [18299277.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1390-4 [18664443.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):520-31 [18680472.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Psychiatr Genet. 2008 Dec;18(6):289-94 [19018234.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):142-53 [19371602.001]
  • [Cites] Cell Biochem Funct. 2009 Dec;27(8):558-67 [19902425.001]
  • [Cites] Environ Health Perspect. 2010 Jan;118(1):144-9 [20056567.001]
  • [Cites] Adv Exp Med Biol. 2010;660:47-60 [20221870.001]
  • [Cites] Eur J Neurol. 2010 Jun 1;17(6):879-81 [20050883.001]
  • [Cites] Chem Biol Interact. 2010 Sep 6;187(1-3):355-61 [20338154.001]
  • [Cites] Neuromolecular Med. 2010 Sep;12(3):217-23 [19826962.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23 [10099836.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] J Lipid Res. 2001 Apr;42(4):528-35 [11290824.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6 [11350209.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Curr Opin Lipidol. 2002 Aug;13(4):357-62 [12151850.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):139-50 [12749719.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):182-4 [12820764.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Mol Med (Berl). 2003 Dec;81(12):766-79 [14551701.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Arch Pathol Lab Med. 1979 Dec;103(13):676-9 [583126.001]
  • [Cites] J Neurol. 1982;227(3):165-9 [6181224.001]
  • [Cites] Indian J Cancer. 1983 Mar;20(1A):86-8 [6873998.001]
  • [Cites] Am J Epidemiol. 1988 Oct;128(4):778-85 [3421243.001]
  • [Cites] Neurologia. 1988 Mar-Apr;3(2):68-70 [2856211.001]
  • [Cites] J Neurosci Nurs. 1992 Oct;24(5):260-4 [1328422.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):598-608 [7916578.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):73-6 [8098250.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] J Neurosurg Sci. 1995 Mar;39(1):27-35 [8568553.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Curr Opin Lipidol. 1996 Apr;7(2):69-76 [8743898.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):334-6 [8896566.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):284-7 [9685159.001]
  • (PMID = 20723250.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  • [Other-IDs] NLM/ PMC2936881
  •  go-up   go-down


33. Careddu MG, Allegrini S, Pesi R, Camici M, Garcia-Gil M, Tozzi MG: Knockdown of cytosolic 5'-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells. Biochim Biophys Acta; 2008 Aug;1783(8):1529-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knockdown of cytosolic 5'-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells.
  • To address this issue, we used a vector based short hairpin RNA (shRNA) strategy to knockdown cN-II activity in human astrocytoma cells.
  • Since cN-II is highly expressed in tumour cells, our finding offers a new possible therapeutical approach especially against primary brain tumours such as glioblastoma, and to ameliorate chemotherapy against leukemia.
  • [MeSH-major] 5'-Nucleotidase / metabolism. Astrocytoma / enzymology
  • [MeSH-minor] Adenoviridae / genetics. Animals. Apoptosis. Cell Line. Cell Line, Tumor. Cell Survival. Humans. Purines / metabolism. RNA Interference. Rats

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445485.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Purines; EC 3.1.3.5 / 5'-Nucleotidase; EC 3.1.3.5 / NT5C2 protein, human
  •  go-up   go-down


34. Smith SF, Simpson JM, Sekhon LH: What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades? J Clin Neurosci; 2005 Nov;12(8):915-20; discussion 921
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades?
  • OBJECTIVE: To determine changes since 1977 in demographic characteristics, tumour frequencies, surgical management, morbidity and survival for 1,339 patients discharged with astrocytoma (A) and oligodendroglioma (O), which comprise the majority of primary brain cancers, recorded prospectively in northern Sydney neurosurgery databases.
  • The proportion of O rose as A fell.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neurosurgical Procedures / statistics & numerical data. Oligodendroglioma / surgery. Postoperative Complications

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326271.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


35. Pan JW, Zhan RY, Tong Y, Zhou YQ, Zhang M: Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. J Zhejiang Univ Sci B; 2005 Jul;6(7):693-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma.
  • OBJECTIVE: To investigate the relationship between the expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and angiogenesis in primary astrocytoma.
  • METHODS: Thirty-seven primary astrocytomas and 4 astrocytic hyperplasia samples were collected and divided into three groups according to histological grade.
  • The intensity of immunoreactivity was graded according to the percentage of positive tumor cells.
  • RESULTS: No eNOS and VEGF were expressed in the astrocytes and vascular endothelium in astrocytic hyperplasia.
  • The expression of eNOS or VEGF was light in low-grade astrocytoma and strong in glioblastoma. eNOS expression in astrocytoma was very positively correlated with VEGF. eNOS and VEGF expression in anaplastic astrocytoma was median in contrast to the low grade astrocytoma and glioblastoma.
  • Lower microvascular density was found in low grade astrocytoma than that in higher grade malignant ones.
  • The expressions of eNOS and VEGF were correlated with microvascular density and tumor malignancy.
  • CONCLUSION: This finding suggests that eNOS and VEGF may have cooperative effect in tumor angiogenesis and play an important role in the pathogenesis of primary astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 1;95(1):189-97 [10607702.001]
  • [Cites] Cardiovasc Res. 1999 Mar;41(3):773-80 [10435050.001]
  • [Cites] Circ Res. 2000 Apr 28;86(8):892-6 [10785512.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Jun;22(3):267-74 [10872046.001]
  • [Cites] Br J Neurosurg. 2000 Dec;14(6):543-8 [11272032.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):568-81 [11166270.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2604-9 [11226286.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):139-48 [11245273.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):607-11 [11267968.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L278-90 [11404271.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1433-41 [11516104.001]
  • [Cites] Ann Anat. 2003 Dec;185(6):549-54 [14704000.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2567-78 [9616228.001]
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):453-62 [9829808.001]
  • [Cites] Nature. 1999 Jun 10;399(6736):597-601 [10376602.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):24-8; discussion 29 [10414562.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):299-304 [10769671.001]
  • (PMID = 15973775.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1389807
  •  go-up   go-down


36. Takei H, Adesina AM, Powell SZ: Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. Neuropathology; 2009 Apr;29(2):181-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex.
  • Subependymal giant cell astrocytoma (SEGA) is a benign, slowly growing tumor typically occurring in the setting of tuberous sclerosis complex (TSC).
  • Histologically, it was composed of interlacing bundles of spindle-shaped tumor cells with thin delicate processes admixed with relatively large pleomorphic cells with abundant glassy eosinophilic cytoplasm, as seen in a SEGA.
  • Immunohistochemically, GFAP, S-100 protein, and neuron specific enolase were positive, and synaptophysin labeled a few tumor cells.
  • Also noted were rare isolated MM cells within the tumor (i.e., tumor-to-tumor metastasis).
  • Tumor metastasis to an occult SEGA is extremely rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Brain / pathology. Brain / physiopathology. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Melanoma / pathology. Melanoma / physiopathology. Melanoma / secondary. Neoplasm Metastasis. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673443.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


37. Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS: Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg; 2006 Jul;105(1):34-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.
  • OBJECT: To investigate the prognostic significance of the volumetrically assessed extent of resection on time to tumor progression (TTP), overall survival (OS), and tumor recurrence patterns, the authors retrospectively analyzed preoperative and postoperative tumor volumes in 102 adult patients from the time of the initial resection of a hemispheric anaplastic astrocytoma (AA).
  • METHODS: The quantification of tumor volumes was based on a previously described method involving computerized analysis of magnetic resonance (MR) images.
  • Analysis of contrast-enhancing tumor volumes on T1-weighted MR images was conducted for 67 patients who had contrast-enhancing tumors.
  • The presence or absence of preresection enhancement, actual volume of this enhancement, and the percentage of preoperative enhancement as it relates to the total T2 tumor volume did not have a statistically significant relationship to TTP or OS.
  • In addition to age, the volume of residual disease measured on T2-weighted MR images was the most significant predictor of TTP (p < 0.001), and residual contrast-enhancing tumor volume was the most significant predictor of OS (p = 0.003) on multivariate analysis.
  • In contrast to low-grade gliomas, there was no statistically significant relationship between the extent of resection and histological characteristics at the time of recurrence, that is, tumor Grade III compared with Grade IV.
  • CONCLUSIONS: Data from this retrospective analysis of a histologically uniform group of hemispheric AAs treated in the MR imaging era suggest that residual tumor volumes, as documented on postoperative imaging studies, may be a prognostic factor for TTP and OS for this patient population.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm, Residual. Predictive Value of Tests. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871879.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


38. Pollicita M, Muscoli C, Sgura A, Biasin A, Granato T, Masuelli L, Mollace V, Tanzarella C, Del Duca C, Rodinò P, Perno CF, Aquaro S: Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line. BMC Neurosci; 2009;10:51
Hazardous Substances Data Bank. N-ACETYLCYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line.
  • RESULTS: To this end, U373 human astrocytoma cells have been directly exposed to X4-using HIV-1IIIB strain, for 1, 3 or 5 days and treated (where requested) with N-acetylcysteine (NAC), a cysteine donor involved in the synthesis of glutathione (GSH, a cellular antioxidant) and apoptosis has been evaluated by FACS analysis.
  • CONCLUSION: Our results support the role of HIV-1-mediated oxidative stress in astrocytic death and the importance of antioxidant compounds in preventing these cellular damages.
  • [MeSH-major] Apoptosis / physiology. Astrocytoma / pathology. HIV-1 / metabolism. Oxidative Stress / physiology. Telomere / pathology
  • [MeSH-minor] Acetylcysteine / pharmacology. Analysis of Variance. Antiviral Agents / pharmacology. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Glutathione / metabolism. Glutathione Disulfide / metabolism. Humans. Microscopy, Electron / methods. Time Factors

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 1999 Aug;12(4):377-81 [10555824.001]
  • [Cites] Exp Gerontol. 2007 Nov;42(11):1039-42 [17869047.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1739-47 [11092534.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):417-24 [11133373.001]
  • [Cites] J Neurosci Res. 2001 Jan 1;63(1):1-9 [11169608.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):745-52 [11409426.001]
  • [Cites] Trends Neurosci. 2001 Jul;24(7):411-6 [11410272.001]
  • [Cites] Free Radic Biol Med. 2001 Sep 15;31(6):824-31 [11557321.001]
  • [Cites] J Leukoc Biol. 2002 Jan;71(1):65-72 [11781381.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):532-40 [11850778.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):598-610 [11850785.001]
  • [Cites] J Am Chem Soc. 2002 Feb 27;124(8):1625-31 [11853436.001]
  • [Cites] Free Radic Biol Med. 2002 Jul 15;33(2):192-200 [12106815.001]
  • [Cites] Hum Mol Genet. 2003 Feb 1;12(3):227-32 [12554677.001]
  • [Cites] BMC Neurosci. 2002 Sep 16;3:13 [12234380.001]
  • [Cites] J Infect Dis. 2003 Jul 15;188(2):232-8 [12854078.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):983-8 [14511933.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1019:278-84 [15247029.001]
  • [Cites] Neurology. 2004 Aug 24;63(4):626-30 [15326233.001]
  • [Cites] Cell. 2004 Oct 29;119(3):355-68 [15507207.001]
  • [Cites] Cell. 1989 Nov 3;59(3):521-9 [2805070.001]
  • [Cites] Lancet. 1989 Dec 2;2(8675):1294-8 [2574255.001]
  • [Cites] Methods Enzymol. 1994;233:594-601 [7912408.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1121-30 [7747806.001]
  • [Cites] Exp Cell Res. 1995 Sep;220(1):186-93 [7664835.001]
  • [Cites] Neurology. 1995 Sep;45(9):1678-83 [7675226.001]
  • [Cites] Stem Cells. 1996 Mar;14(2):239-48 [8991544.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1373-81 [8891117.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):1979-90 [8903316.001]
  • [Cites] Cancer Surv. 1996;28:197-216 [8977036.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2700-8 [9006907.001]
  • [Cites] Free Radic Biol Med. 1997;22(5):775-85 [9119245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1967-72 [9050888.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):905-8 [9175737.001]
  • [Cites] J Leukoc Biol. 1997 Jul;62(1):54-9 [9225993.001]
  • [Cites] Exp Cell Res. 1998 Feb 25;239(1):152-60 [9511733.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):569-74 [9560153.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Mar;57(3):257-67 [9600218.001]
  • [Cites] Free Radic Biol Med. 1998 Apr;24(6):885-93 [9607597.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1011-9 [9920850.001]
  • [Cites] J Med Primatol. 1999 Feb;28(1):1-10 [10372535.001]
  • [Cites] FEBS Lett. 1999 Jun 25;453(3):365-8 [10405177.001]
  • [Cites] J Neuroimmunol. 2004 Dec;157(1-2):176-84 [15579295.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Anal Biochem. 1980 Jul 15;106(1):55-62 [7416469.001]
  • [Cites] Am J Pathol. 1980 Nov;101(2):331-44 [7435541.001]
  • [Cites] Science. 1988 Feb 5;239(4840):586-92 [3277272.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Nov;10(2):89-94 [16358816.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):1-11 [17150040.001]
  • [Cites] J Med Virol. 2007 May;79(5):639-46 [17387751.001]
  • [Cites] Virology. 2007 Jul 5;363(2):462-72 [17336361.001]
  • [Cites] Neurochem Int. 2000 Mar;36(3):185-91 [10676851.001]
  • (PMID = 19463156.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; GAN16C9B8O / Glutathione; ULW86O013H / Glutathione Disulfide; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC2694812
  •  go-up   go-down


39. He S, Dibas A, Yorio T, Prasanna G: Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells. Exp Biol Med (Maywood); 2007 Mar;232(3):370-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
  • Endothelin-1 (ET-1) is a potent mitogen for many cells, especially when its levels are elevated under pathological conditions, as seen in tumor cell progression and astroglial activation in neuropathies.
  • Treatment with PD98059 and U0126 (MEK inhibitors) inhibited not only ET-1-induced cell proliferation but also ET-1-activated phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) in U373MG astrocytoma cells.
  • [MeSH-minor] Astrocytoma / metabolism. Astrocytoma / pathology. Astrocytoma / physiopathology. Calcium Signaling / drug effects. Cell Line, Tumor. Endothelin B Receptor Antagonists. Enzyme Inhibitors / pharmacology. Estrenes / pharmacology. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Inositol 1,4,5-Trisphosphate / metabolism. Isoenzymes / antagonists & inhibitors. Isoenzymes / metabolism. Methionine / analogs & derivatives. Methionine / pharmacology. Models, Biological. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation / drug effects. Protein Kinase C / antagonists & inhibitors. Protein Kinase C / metabolism. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors. Proto-Oncogene Proteins p21(ras) / metabolism. Pyrrolidinones / pharmacology. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, Endothelin B / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327470.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY11979
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin B Receptor Antagonists; 0 / Endothelin-1; 0 / Enzyme Inhibitors; 0 / Estrenes; 0 / FTI 277; 0 / Isoenzymes; 0 / Protein Kinase Inhibitors; 0 / Pyrrolidinones; 0 / Receptor, Endothelin B; 112648-68-7 / 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; 85166-31-0 / Inositol 1,4,5-Trisphosphate; AE28F7PNPL / Methionine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


40. See SJ, Ty A, Wong MC: Salvage chemotherapy in progressive high-grade astrocytoma. Ann Acad Med Singapore; 2007 May;36(5):343-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy in progressive high-grade astrocytoma.
  • INTRODUCTION: Despite aggressive multidisciplinary interventions, patients with high-grade astrocytomas experience tumour progression or recurrence.
  • MATERIALS AND METHODS: A retrospective review of relevant clinical and radiographic information of patients who received at least one cycle of salvage chemotherapy for progressive high-grade astrocytoma at the National Cancer Center, Singapore, from March 2004 to September 2006, was conducted.
  • RESULTS: Twenty-four patients (13 glioblastomas, 11 anaplastic astrocytomas) had received chemotherapy as salvage treatment following progression of their high-grade astrocytoma.
  • For patients with anaplastic astrocytoma, the 12-month survival rate was 73%.
  • CONCLUSION: Durable disease control and prolonged survival were seen in a significant portion of selected patients with progressive high-grade astrocytoma who received salvage chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Glioblastoma / drug therapy. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549281.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


41. Rudnick JD, Phuphanich S, Chu R, Mazer M, Wang H, Serrano N, Francisco M, Black KL, Wheeler C, Yu J: A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):2033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
  • : 2033 Background: Our prior immunotherapy trials demonstrated efficacy in generating a tumor specific immune response in malignant glioma and the potential for high tumor-specific toxicity and sustained tumoricidal activity.
  • METHODS: We exploited this synergistic effect to maintain a cytotoxic environment around the tumor milieu.
  • Patients with high-grade glioma were eligible after maximal resection with biodegradable carmustine (BCNU) wafer placement.
  • Screening leukapheresis is used to isolate mononuclear cells which are differentiated into dendritic cells, pulsed with tumor lysate, and then 3 intradermal vaccines are administered at 2-week intervals.
  • The histology included 3 newly diagnosed glioblastoma multiforme (GBM), 8 recurrent GBM, 2 newly diagnosed anaplastic astrocytoma (AA), and 2 recurrent AA.
  • A stable disease interval of 13 to 90 weeks was observed for patients who received vaccine.
  • The 3 newly diagnosed GBM patients have stable disease (18 to 71 weeks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964627.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Domínguez-Páez M, Weil-Lara B, Rodríguez-Barceló S, Medina-Imbroda JM, Puch-Ramírez M, Ros-López B, Arráez-Sánchez MA: [Pilomyxoid astrocytoma. Three cases and review]. Neurocirugia (Astur); 2010 Feb;21(1):22-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilomyxoid astrocytoma. Three cases and review].
  • [Transliterated title] Astrocitomas pilomixoides. Presentación de tres casos y revisión de la literatura.
  • INTRODUCTION: Pilomyxoid astrocytoma (PMA) is a central nervous system (CNS) tumour with peculiar clinicopathological features, that turn it into an entity different from pilocytic astrocytoma (PA).
  • It appears in 2007 WHO classification of tumours of the CNS as an PA subtype belonging to the group of astrocytic tumours.
  • [MeSH-major] Astrocytoma. Central Nervous System Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186371.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


43. Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Mehr Azin M: Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol; 2008 Nov;134(11):1173-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor.
  • ATM alterations were found in medulloblastomas, gliomas, but not in astrocytoma.
  • We could observe this polymorphism, heterozygously, in a proband affected with astrocytoma and traced it through her pedigree.
  • We propose the three-hit hypothesis as a triangle initiators includes D1853N as a first predisposing hit, IVS 38- 63T --> A as a second hit deriving from the first somatic evolution before differentiation and IVS 38- 30 A --> G as a third hit through the development of an astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Ataxia Telangiectasia Mutated Proteins. Cell Cycle / genetics. Cloning, Molecular. DNA Repair. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Gene Amplification. Humans. Immunohistochemistry. Male. Pedigree. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18465141.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


44. Tsutsumi S, Higo T, Kondo A, Abe Y, Yasumoto Y, Ito M: Atypical cervical astrocytoma manifesting as occipitalgia. Neurol Med Chir (Tokyo); 2007 Aug;47(8):371-4
MedlinePlus Health Information. consumer health - Headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical cervical astrocytoma manifesting as occipitalgia.
  • Cervical MR imaging revealed a cervical intramedullary tumor.
  • Intraoperatively the subpial tumor was found to stretch the 3rd-5th dorsal nerve roots posteriorly, which was thought to cause the intolerable headache.
  • Total tumor resection was achieved without requiring myelotomy using electrophysiological monitoring with somatosensory and motor evoked potentials.
  • Histological examination identified diffuse astrocytoma.
  • Cervical astrocytoma of subpial location is a very rare cause of headache in adults.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / pathology. Headache / etiology. Spinal Cord / pathology. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721055.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


45. Haris M, Husain N, Singh A, Husain M, Srivastava S, Srivastava C, Behari S, Rathore RK, Saksena S, Gupta RK: Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma. J Comput Assist Tomogr; 2008 Nov-Dec;32(6):955-65
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma.
  • OBJECTIVE: To look for the impact of leak correction on correlation of perfusion indices with microvessel density (MVD) and vascular endothelial growth factor (VEGF) in astrocytomas.
  • METHODS: Dynamic contrast-enhanced magnetic resonance imaging was performed in 64 patients with varying grades of astrocytoma.
  • MVD and VEGF-expressing cells were quantified from the excised tumor tissues and were correlated with perfusion metrics.
  • RESULTS: Perfusion indices showed significant difference among the astrocytoma grades.
  • The corrected rCBV correlated (r = 0.853, P = <0.001) strongly, whereas the uncorrected rCBV (r = 0.592, P = <0.001) and k(trans) (r = 0.498, P = 0.001) correlated moderately with tumor grade.
  • The corrected rCBV discriminated 100% low-grade from high-grade astrocytoma, while uncorrected rCBV did this in 95.5% low-grade and 71.4% high-grade astrocytoma.
  • CONCLUSIONS: Corrected rCBV better correlates with grade and is more accurate in discriminating low-grade from high-grade astrocytoma compared with uncorrected rCBV.
  • [MeSH-major] Artifacts. Astrocytoma / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Gadolinium DTPA. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19204461.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Vascular Endothelial Growth Factor A; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


46. Facoetti A, Ranza E, Nano R: Proliferation and programmed cell death: role of p53 protein in high and low grade astrocytoma. Anticancer Res; 2008 Jan-Feb;28(1A):15-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation and programmed cell death: role of p53 protein in high and low grade astrocytoma.
  • p53 is a cell cycle regulator that has been well-recognized as the key molecule that triggers the induction and the control of cell proliferation and apoptosis in a wide variety of tumours, including astrocytoma.
  • Previous studies of the correlations between proliferation and apoptotic index with p53 expression in astrocytic tumours have remained inconclusive.
  • The aim of this study was to investigate the correlation of p53 expression with the apoptotic index (AI) and the cell proliferation index (PI) in pilocytic astrocytoma (PA) and glioblastoma multiforme (GBM).
  • A correlation of p53 expression with AI and PI was found in pilocytic astrocytoma but not in glioblastoma, probably because of the mutated p53 phenotype in the latter.
  • [MeSH-major] Apoptosis / physiology. Astrocytoma / pathology. Central Nervous System Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383819.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


47. Sharma MK, Watson MA, Lyman M, Perry A, Aldape KD, Deák F, Gutmann DH: Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology; 2006 Jan 10;66(1):127-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma.
  • Using whole genome expression microarray technology to discover clinically relevant biomarkers for pilocytic astrocytoma (PA), the authors identified matrilin-2 as a unique mRNA overexpressed in PA.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Extracellular Matrix Proteins / genetics. Glycoproteins / genetics

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401863.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / Glycoproteins; 0 / MATN2 protein, human; 0 / Matrilin Proteins; 0 / RNA, Messenger
  •  go-up   go-down


48. Malhan P, Husain N, Bhalla S, Gupta RK, Husain M: Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.
  • Histological classification and grading are prime procedures in the management of patients with astrocytoma, providing vital data for therapeutic decision making and prognostication.
  • However, it has limitations in assessing biological tumor behavior.
  • This study was carried out to compare proliferative indices using proliferating cell nuclear antigen (PCNA), extent of p53 expression and micro vessel morphometric parameters in patients with low grade and anaplastic astrocytoma.
  • Twenty-five patients, each of grade II and grade III astrocytoma were evaluated using monoclonal antibodies to PCNA, p53 protein and factor VIII related antigen.
  • Patients with grade III astrocytoma had higher PCNA and p53 labeling indices as compared with grade II astrocytoma (29.14 plus/minus 9.87% vs. 16.84 plus/minus 6.57%, p 0.001; 18.18 plus/minus 6.14% vs. 6.14 plus/minus 7.23%, p 0.001, respectively).
  • Micro vessel percentage area of patients with grade III astrocytoma was also (4.26 plus/minus 3.70 vs. 1.05 plus/minus 0.56, p 0.001), higher along with other micro vessel morphometric parameters.
  • Discordance between histology and one or more IHC parameters was seen in 5/25 (20%) of patients with grade III astrocytoma and 9/25 (36%) of patients with grade II disease.
  • Increased proliferative fraction, genetic alterations and neovascularization mark biological aggressiveness in astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / pathology. Neovascularization, Pathologic. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090216.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


49. Sekula RF Jr, Marchan EM, Quigley MR, Frederickson AM, Pu C: A case of an elderly adult presenting with obstructive hydrocephalus secondary to a rare hemorrhagic suprasellar pilocytic astrocytoma. Clin Neuropathol; 2008 Nov-Dec;27(6):396-9
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of an elderly adult presenting with obstructive hydrocephalus secondary to a rare hemorrhagic suprasellar pilocytic astrocytoma.
  • Urgent surgery was performed and final pathology eventuated a pilocytic astrocytoma.
  • Although rare cases of suprasellar pilocytic astrocytoma in children and adults have been reported, we report an interesting case of a hemorrhagic suprasellar pilocytic astrocytoma in an elderly adult (without prior anticoagulant use) causing impending brain herniation secondary to obstructive hydrocephalus.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Hemorrhage / etiology. Hydrocephalus / etiology


50. Hamir AN, Picton R, Blythe LL, Heidel JR: Diagnostic exercise: astrocytoma with involvement of medulla oblongata, spinal cord, and spinal nerves in a raccoon (Procyon lotor). Vet Pathol; 2008 Nov;45(6):949-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic exercise: astrocytoma with involvement of medulla oblongata, spinal cord, and spinal nerves in a raccoon (Procyon lotor).
  • Described are clinical signs and pathologic and immunohistochemical findings in an adult female raccoon (Procyon lotor) with an astrocytoma that involved medulla, cervical spinal cord, and roots of the cervical spinal nerves.
  • This appears to be the only reported case of astrocytoma that involved multiple anatomic sites in the central nervous system of this raccoon.
  • [MeSH-major] Astrocytoma / veterinary. Central Nervous System Neoplasms / veterinary. Medulla Oblongata / pathology. Raccoons. Spinal Cord / pathology. Spinal Nerves / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984803.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Gu S, Bao N, Yin MZ: Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature. J Child Neurol; 2010 Feb;25(2):216-21
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for desmoplastic infantile astrocytoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature.
  • Desmoplastic infantile astrocytoma is a rare low-grade malignant brain tumor found in infants.
  • A case of desmoplastic infantile astrocytoma, including its clinical manifestations, pathological characteristics, differential diagnosis, treatment, and prognosis, is reported.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Cranial Fontanelles / surgery. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671888.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


52. Jang FF, Wei W, De WM: Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma. J Ayub Med Coll Abbottabad; 2008 Apr-Jun;20(2):105-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
  • BACKGROUND: Astrocytoma is the most malignant intracranial neoplasm and is characterized by high neovascularization and peritumoural brain oedema.
  • METHODS: The expression of two angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor were investigated using immunohistochemistry for astrocytoma from 82 patients and 11 normal human tissues.
  • RESULTS: The expression of vascular endothelial growth factor and basic fibroblast growth factor positively correlate with the pathological grade of astrocytoma, microvessel density numbers and brain oedema, which may be responsible for the increased tumour neovascularization and peritumoural brain oedema.
  • CONCLUSION: The results support the idea that inhibiting vascular endothelial growth factor and basic fibroblast growth factor are useful for the treatment of human astrocytoma and to improve patient's clinical outcomes and prognosis.
  • [MeSH-major] Astrocytoma / blood supply. Brain Edema / etiology. Brain Neoplasms / blood supply. Fibroblast Growth Factor 2 / biosynthesis. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385471.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


53. Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM: Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. J Clin Oncol; 2009 May 20;27(15_suppl):2042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.
  • Safety and efficacy of intracerebral inoculations of G207 to patients suffering from recurrent malignant gliomas have been demonstrated in previous clinical trials.
  • METHODS: In this phase I clinical trial, a total of 1 x 10<sup>9</sup> plaque forming units (pfu) G207 were administered by five stereotactic injections of 0.2 mL each into regions of recurrent malignant glioma defined by MRI, followed by focal radiation therapy 24 hours post injection.
  • Included patients suffered from inoperable pathologically proven recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) which was progressive despite radiotherapy or chemotherapy and failed external beam radiotherapy > 5 Gray prior to study enrolment.
  • The 2 patients with initial PR (1xGBM, 1xAA) were re-treated with G207/Irradiation at time point of tumor recurrence, showing PR one month after re-treatment again.
  • Within persistent areas of tumor, HSV staining was present by using a polyclonal antibody for HSV, indicating intratumoral G207 replication (proof of concept).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Simonelli M, Banna G, Navarria P, Di Ieva A, Zucali P, De Vincenzo F, Gaetani P, Condorelli R, Rodriguez Y Baena R, Scorsetti M, Santoro A: Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas.
  • : e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.
  • Currently, the addition of chemotherapy to radiotherapy (RT) for newly diagnosed anaplastic gliomas is not sustained by available data.
  • We evaluated the addition of temozolomide (TMZ) to radiotherapy for newly diagnosed anaplastic gliomas in terms of tolerability, progression-free survival (PFS), and overall survival (OS).
  • METHODS: Since September 2004, following initial surgery, patients (pts) with histologically confirmed anaplastic glioma, Karnofsky Performance Status (KPS) ≥40, adequate organ function, no prior chemotherapy, were treated with RT to limited fields once daily at 2 Gy per fraction, 5 days a week, for a total of 60 Gy with concomitant TMZ (75 mg/m<sup>2</sup> for 7 days a week) followed by 6 cycles of maintenance TMZ at 200 mg/m<sup>2</sup> on days 1-5 every 28 days.
  • Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.
  • CONCLUSIONS: The addition of temozolomide to radiation therapy for newly diagnosed anaplastic gliomas is well tolerated and seems active; efficacy needs confirmation in a randomized clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Abacioglu MU, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M: Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma.
  • : e13018 Background: The study was aimed to evaluate the efficacy of TMZ on a protracted dose-dense schedule after standard 5-day TMZ regimen in patients with progressive high-grade glioma.
  • METHODS: In this phase II prospective study, patients who had progression on standard 5-day TMZ for recurrence (group 1) or recurrence after concurrent radiotherapy+TMZ and ≥ 2 cycles of adjuvant TMZ (group 2) for high-grade glioma received TMZ 100 mg/m2× 21 q28 days until progression according to MacDonald's criteria.
  • The histopathology was glioblastoma in 18 and grade 3 glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma) in 7.
  • The best response during treatment was partial response in 2 (8%), stable disease in 9 (36%), and progression in 9 (36%) out of 20 patients assessed.
  • CONCLUSIONS: Protracted dose-dense TMZ after 5-day schedule for recurrent or progressive disease has modest efficacy with tolerable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962826.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Guo XL, Zhong YF, Sun YH, Liu HH, Jin B, Liang W, Li XS: [Muscle atrophy of hand as an initial sign in a patient with protoplasmic astrocytoma: a case report and literature review]. Beijing Da Xue Xue Bao; 2008 Dec 18;40(6):649-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Muscle atrophy of hand as an initial sign in a patient with protoplasmic astrocytoma: a case report and literature review].
  • We reported a rare case of protoplasmic astrocytoma presenting small muscle atrophy of the right hand as an initial sign.
  • CT and MRI revealed multiply expansive intracranial lesion in left hemisphere, which was highly suspected of cerebral echinococcus or Balo disease.
  • The patient underwent surgical excision and pathological report was protoplasmic astrocytoma, with glial fibrillary acidic protein (GFAP, +++) of immunohistochemical method.
  • We reviewed clinical features, radiological manifestations and pathology of protoplasmic astrocytoma with medical literature documents.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Muscular Atrophy / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19088841.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


57. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C: Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci; 2008 Feb;15(2):114-21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
  • Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma.
  • We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant / methods. Dendritic Cells / immunology. Immunotherapy, Active / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083572.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / Cancer Vaccines; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


58. Ess KC, Kamp CA, Tu BP, Gutmann DH: Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology; 2005 Apr 26;64(8):1446-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex.
  • Children with tuberous sclerosis complex (TSC) harbor developmental brain abnormalities (cortical tubers) and low-grade tumors (subependymal giant cell astrocytomas [SEGAs]).
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Differentiation / genetics. Tuberous Sclerosis / genetics. Tuberous Sclerosis / metabolism
  • [MeSH-minor] Adolescent. Animals. Cell Lineage / genetics. Child. Disease Models, Animal. Female. Gene Expression Profiling. Gene Expression Regulation, Developmental / genetics. Genetic Markers / genetics. Humans. Infant. Male. Mice. Mice, Knockout. Nerve Tissue Proteins / genetics. Neurons / metabolism. Stem Cells / metabolism. Tumor Suppressor Proteins / genetics


59. White JB, Piepgras DG, Scheithauer BW, Parisi JE: Rate of spontaneous hemorrhage in histologically proven cases of pilocytic astrocytoma. J Neurosurg; 2008 Feb;108(2):223-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rate of spontaneous hemorrhage in histologically proven cases of pilocytic astrocytoma.
  • The rate of tumor-related intracranial hemorrhage is variably reported from <1 to 14.6%.
  • Hemorrhage in primary gliomas occurs in 3.7-7.2% of gliomas, mainly in glioblastoma muliforme and oligodendroglioma with low-grade astrocytomas accounting for <1%.
  • Hemorrhage associated with pilocytic astrocytomas (PAs) is only sporadically reported.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Cerebral Hemorrhage / etiology


60. Foreman NK, Gore L, Wells D, Straessle J, Heideman R, Donson AM: Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. Pediatr Blood Cancer; 2006 Sep;47(3):293-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
  • BACKGROUND: Juvenile pilocytic astrocytomas (JPAs) are the most common central nervous system tumors in children.
  • To explore the possibility for a novel therapeutic approach we measured the effect of the epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitor gefitinib on five JPA primary cell-cultures.
  • Of interest, it appears that the anti-tumor effect of gefitinib in JPA cell-cultures may be mediated through a pathway other than EGFR inhibition.
  • [MeSH-major] Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Quinazolines / pharmacology
  • [MeSH-minor] Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Flow Cytometry. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Thymidine / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206208.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA49981
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; VC2W18DGKR / Thymidine
  •  go-up   go-down


61. Eddaoudi A, Townsend-Nicholson A, Timms JF, Schorge S, Jayasinghe SN: Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells. Analyst; 2010 Oct;135(10):2600-12
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells.
  • These findings support the further development of bio-electrosprays as a viable technology for a wide diversity of tissue engineering, regenerative biology, advanced cellular therapeutics and medicinal applications, having significance in the clinic.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694206.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / G0601440; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Maleimides; 0 / Potassium Channels; 0 / Receptor, Muscarinic M3; 0 / Tumor Necrosis Factor-alpha; 0 / bisindolylmaleimide VIII; SY7Q814VUP / Calcium
  •  go-up   go-down


62. Quick Q, Skalli O: Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. Exp Cell Res; 2010 Apr 15;316(7):1137-47
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells.
  • Here, we have examined whether the two highly homologous non-muscle alpha-actinin isoforms 1 and 4 exhibit functional differences in astrocytoma cells.
  • The protein levels of these isoforms were differentially regulated during the development and progression of astrocytomas, as alpha-actinin 1 was higher in astrocytomas compared to normal brains whereas alpha-actinin 4 was elevated in high-grade astrocytomas compared to normal brains and low grade astrocytomas.
  • RNAi demonstrated contrasted contributions of alpha-actinin 1 and 4 to the malignant behavior of U-373, U-87 and A172 astrocytoma cells.
  • While alpha-actinin 1 appeared to favor the expansion of U-373, U-87 and A172 astrocytoma cell populations, alpha-actinin 4 played this role only for U-373 cells.
  • Finally, in the three astrocytoma cell lines examined, alpha-actinin 1 and 4 had contrasted biochemical properties as alpha-actinin 4 was significantly more abundant in the actin cytoskeleton than alpha-actinin 1.
  • Collectively, these findings suggest that alpha-actinin 1 and 4 are differentially regulated during the development and progression of astrocytomas because each of these isoforms uniquely contributes to distinct malignant properties of astrocytoma cells.
  • [MeSH-major] Actinin / physiology. Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Movement / genetics. rhoA GTP-Binding Protein / physiology
  • [MeSH-minor] Brain / metabolism. Cell Proliferation. Cell Survival / genetics. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Signal Transduction / genetics. Signal Transduction / physiology. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20156433.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTN1 protein, human; 0 / ACTN4 protein, human; 11003-00-2 / Actinin; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


63. Samuelson C, Forman KM, Smith S: Idiopathic thrombocytopenic purpura associated with an astrocytoma. BMJ Case Rep; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic thrombocytopenic purpura associated with an astrocytoma.
  • She underwent treatment with intravenous immunoglobulin (IVIg) and steroids to increase her platelet count, followed by excision of the lesion, which was found to be a benign pilocytic astrocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22419950.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028124
  •  go-up   go-down


64. Gupta M, Djalilvand A, Brat DJ: Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol; 2005 Nov;124(5):755-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
  • Diffuse gliomas are the most common brain tumors and include astrocytomas, oligodendrogliomas, and oligoastrocytomas.
  • Their correct pathologic diagnosis requires the ability to distinguish astrocytic from oligodendroglial differentiation in histologic sections, a challenging feat even for the most experienced neuropathologist.
  • Interobserver variability in the diagnosis of diffuse gliomas has been high owing to subjective diagnostic criteria, overlapping morphologic features, and variations in training and practice among pathologists.
  • Combined loss of chromosomes 1p and 19q is a genetic signature of oligodendrogliomas, whereas gains of chromosome 7 in the setting of intact 1p/19q are more typical of astrocytomas.
  • Detection of amplified epidermal growth factor receptor favors the diagnosis of high-grade astrocytomas over anaplastic oligodendroglioma, which is especially relevant for small cell astrocytomas.
  • Strong nuclear staining for p53 often reflects TP53 mutation and is typical of low-grade astrocytomas.
  • Diffuse gliomas remain a diagnostic challenge, and new markers are needed for proper classification and directed therapies.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Genes, p53. Genetic Markers. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Mutation. Receptor, Epidermal Growth Factor / genetics


65. Töteberg-Harms M, Paulsen F, Duncker GI, Sel S: [Clinical course of a solitary retinal astrocytoma]. Ophthalmologe; 2009 Oct;106(10):921-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course of a solitary retinal astrocytoma].
  • Retinal astrocytomas are benign tumors of the retina.
  • It is also known that they can be part of a phakomatosis syndrome (i.e., tuberous sclerosis or neurofibromatosis).
  • Because retinal astrocytomas have a slow growth rate, yearly controls by an ophthalmologist with interdisciplinary consultation are adequate.
  • Some uncommon cases have been reported in which the tumor has grown more aggressively.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Retinal Neoplasms / diagnosis. Retinal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmologe. 2010 Apr;107(4):377-8; author reply 378 [20379723.001]
  • (PMID = 19484244.001).
  • [ISSN] 1433-0423
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Facoetti A, Ranza E, Grecchi I, Benericetti E, Ceroni M, Morbini P, Nano R: Immunohistochemical evaluation of minichromosome maintenance protein 7 in astrocytoma grading. Anticancer Res; 2006 Sep-Oct;26(5A):3513-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of minichromosome maintenance protein 7 in astrocytoma grading.
  • The minichromosome maintenance (MCM) proteins, which play an important role in eukaryotic DNA replication, represent a group of proteins that are currently under investigation as novel diagnostic tumor markers.
  • In the present study, the expressions of MCM7 and Ki67 were estimated in 66 primary human astrocytomas in relation to tumor grade (Grade I-IV, WHO).
  • In addition, a stronger increase of the MCM7 labelling index, in relation to the tumor aggressiveness, was observed.
  • [MeSH-major] Astrocytoma / pathology. Cell Cycle Proteins / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Minichromosome Maintenance Complex Component 7. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094475.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 3.6.4.12 / MCM7 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 7
  •  go-up   go-down


67. Reardon DA, Rich JN, Friedman HS, Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol; 2006 Mar 10;24(8):1253-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the treatment of malignant astrocytoma.
  • Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms.
  • Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress.
  • As cell-signaling alterations linked to the development and progression of gliomas are being increasingly elucidated, targeted therapies have rapidly entered preclinical and clinical evaluation.
  • The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.
  • [MeSH-major] Astrocytoma / therapy. Central Nervous System Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525180.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 209
  •  go-up   go-down


68. Ranza E, Bertolotti A, Facoetti A, Mariotti L, Pasi F, Ottolenghi A, Nano R: Influence of imatinib mesylate on radiosensitivity of astrocytoma cells. Anticancer Res; 2009 Nov;29(11):4575-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
  • The objective of this study was to determine whether gamma radiation could sensitize astrocytoma cell lines to the effects of imatinib in vitro.
  • For this purpose, T98G and MOG-G-UVW astrocytoma cells were treated with imatinib alone or in combination with gamma radiation.
  • [MeSH-major] Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Benzamides. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Gamma Rays. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Imatinib Mesylate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032406.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Kim SJ, Jeong HJ, Kim BK, Kim NH, Kim JS, Choi KS, Lee HJ, Kang ST, Shin SS, Kim WI, Eom HS, Lee KM, Um JY, Hong SH, Kim HM: Anti-inflammatory effect of jeongshintang through suppression of p38 activation in human astrocytoma, U373MG cells. Exp Mol Pathol; 2006 Aug;81(1):85-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-inflammatory effect of jeongshintang through suppression of p38 activation in human astrocytoma, U373MG cells.
  • Jeongshintang (JST) is a Korean herbal prescription, which has been successfully used for cerebral diseases.
  • However, the anti-inflammatory effect of JST on Alzheimer's disease (AD) is still not fully understood.
  • These results demonstrated that JST has an anti-inflammatory effect, which might explain its beneficial effect in the treatment of various neurodegenerative diseases such as AD.
  • [MeSH-minor] Amyloid beta-Peptides / toxicity. Astrocytoma. Cell Line, Tumor. Cyclooxygenase 2. Dinoprostone / antagonists & inhibitors. Enzyme Activation / drug effects. Humans. Interleukin-1 / toxicity. Interleukin-6 / antagonists & inhibitors. Interleukin-8 / antagonists & inhibitors. Membrane Proteins / antagonists & inhibitors. Peptide Fragments / toxicity. Protein Kinase Inhibitors / pharmacology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698013.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Anti-Inflammatory Agents; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Membrane Proteins; 0 / Neuroprotective Agents; 0 / Peptide Fragments; 0 / Plant Extracts; 0 / Protein Kinase Inhibitors; 0 / amyloid beta-protein (1-42); 0 / jeongshintang; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


70. Zuzak TJ, Poretti A, Drexel B, Zehnder D, Boltshauser E, Grotzer MA: Outcome of children with low-grade cerebellar astrocytoma: long-term complications and quality of life. Childs Nerv Syst; 2008 Dec;24(12):1447-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with low-grade cerebellar astrocytoma: long-term complications and quality of life.
  • OBJECTS: To study the long-term outcome of surgically treated low-grade cerebellar astrocytomas in children.
  • In 21 of 31 survivors (median follow-up time 7.9 years; range 5.6-27.4 years) who agreed to participate, tumor control, neurological and cognitive complications, and their impact on behavioral and emotional adjustment and health-related quality of life (HRQoL) were comprehensively assessed qualitatively and quantitatively.
  • CONCLUSION: Childhood low-grade cerebellar astrocytomas have an excellent cure rate by tumor surgery alone.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Quality of Life
  • [MeSH-minor] Activities of Daily Living. Child. Cognition Disorders / diagnosis. Cognition Disorders / etiology. Disease-Free Survival. Follow-Up Studies. Health Status Indicators. Humans. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Survivors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690461.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Liang ML, Ma J, Ho M, Solomon L, Bouffet E, Rutka JT, Hawkins C: Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol; 2008 May;87(3):247-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tyrosine kinase expression in pediatric high grade astrocytoma.
  • The over-expression of several receptor tyrosine kinases in adult high grade astrocytomas (HGA) led to trials of tyrosine kinase inhibitors in these patients.
  • Here we investigated the protein expression profile of a series of pediatric HGAs.
  • Following institutional ethical approval, clinical information and tumor samples were obtained for 42 HGA patients.
  • Further, there were distinct differences in protein expression between pediatric and adult HGAs suggesting that EGFR kinase inhibitors may not be beneficial for treatment of HGA in the pediatric age group and pointing to the need to study pediatric astrocytomas as distinct entities from adult astrocytomas.
  • [MeSH-major] Astrocytoma / enzymology. Brain Neoplasms / enzymology. Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Gene Expression. Humans. Immunohistochemistry. Infant. Kaplan-Meier Estimate. Male. PTEN Phosphohydrolase / biosynthesis. Prognosis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Tissue Array Analysis. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193393.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


72. Hashioka S, Klegeris A, Schwab C, McGeer PL: Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging; 2009 Dec;30(12):1924-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells.
  • Astrocytes and microglia become activated in a broad spectrum of inflammatory neurodegenerative diseases.
  • To investigate the neurotoxic potential of human astrocytes, we exposed them and human astrocytic U-373 MG cells to a variety of inflammatory stimulants.
  • Other powerful inflammatory stimulants such as lipopolysaccharide (0.5mug/ml), tumor necrosis factor-alpha (10ng/ml) and interleukin-1beta (10ng/ml), alone or in combination, were without effect.
  • Finally, using human postmortem material, we showed sharp upregulation of the IFNGR on activated astrocytes in affected areas in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis.
  • These findings suggest that activated astrocytes may become neurotoxic when stimulated by IFN-gamma and may therefore exacerbate the pathology in a spectrum of neurodegenerative diseases.
  • [MeSH-major] Astrocytes / physiology. Astrocytoma / physiopathology. Cell Survival. Interferon-gamma / metabolism
  • [MeSH-minor] Alzheimer Disease / metabolism. Amyotrophic Lateral Sclerosis / metabolism. Brain / immunology. Brain / physiopathology. Cell Line, Tumor. Humans. Janus Kinases / antagonists & inhibitors. Janus Kinases / metabolism. Lipopolysaccharides / metabolism. Multiple Sclerosis / metabolism. Parkinson Disease / metabolism. Receptors, Interferon / metabolism. Signal Transduction. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18375019.001).
  • [ISSN] 1558-1497
  • [Journal-full-title] Neurobiology of aging
  • [ISO-abbreviation] Neurobiol. Aging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / Receptors, Interferon; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; EC 2.7.10.2 / Janus Kinases
  •  go-up   go-down


73. Dukhande VV, Malthankar-Phatak GH, Hugus JJ, Daniels CK, Lai JC: Manganese-induced neurotoxicity is differentially enhanced by glutathione depletion in astrocytoma and neuroblastoma cells. Neurochem Res; 2006 Nov;31(11):1349-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manganese-induced neurotoxicity is differentially enhanced by glutathione depletion in astrocytoma and neuroblastoma cells.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glutathione / physiology. Manganese Poisoning / pathology. Neuroblastoma / pathology
  • [MeSH-minor] Antimetabolites / toxicity. Buthionine Sulfoximine / toxicity. Cell Death / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Humans. Nerve Degeneration / pathology


74. Matsuda K, Sakurada K, Mouri W, Saino M, Sato S, Saito S, Kayama T, Nakazato Y: [Operative case of isomorphic astrocytoma]. Brain Nerve; 2007 Aug;59(8):881-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative case of isomorphic astrocytoma].
  • Diffuse astrocytomas are classified as WHO Grade II tumors.
  • Recently, a subtype presenting with better prognosis has been proposed, and it is known as "isomorphic astrocytoma."
  • A clinical case that we encountered was believed to be categorized as this subtype; it has been presented in this report.
  • The tumor was resected under awake surgery.
  • The pathological diagnosis was diffuse astrocytoma, but this tumor was considered to be the isomorphic subtype.
  • Some parts of the tumor showed a relatively high MIB-1 labeling index (LI) of 9.2%, and additional 50-Gy radiotherapy was performed.
  • Isomorphic astrocytoma is characterized by prolonged epileptic seizures, a low MIB-1 LI, and better prognosis.
  • In our case, since the MIB-1 LI was higher in some parts of the tumor, the appropriate therapy for WHO Grade II tumors was performed.
  • However, this case was considered representative of isomorphic astrocytoma.
  • No reports of this tumor subtype have been previously described in Japan.
  • Therefore, this report is the first case of isomorphic astrocytoma reported to Japanese literature.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713125.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Ronghe M, Hargrave D, Bartels U, Tabori U, Vaidya S, Chandler C, Kulkarni A, Bouffet E: Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer; 2010 Sep;55(3):471-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem.
  • BACKGROUND: Radiotherapy remains a widely accepted postoperative treatment modality for unresectable or recurrent low-grade glioma (LGG).
  • After a median follow-up of 57 months (range 20-136) from initiation of chemotherapy all children are alive and 11 remain progression free (1 complete response, 8 with partial response + minor response, and 2 stable diseases).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Stem. Brain Stem Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / drug therapy. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20535831.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


76. Vilaplana D, Castilla M, Poposki V, Alameda F, Shields CL: Acquired retinal astrocytoma managed with endoresection. Retina; 2006 Nov-Dec;26(9):1081-2
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired retinal astrocytoma managed with endoresection.
  • [MeSH-major] Astrocytoma / surgery. Ophthalmologic Surgical Procedures. Retinal Neoplasms / surgery
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diathermy. Fluorescein Angiography. Fluorocarbons / administration & dosage. Humans. Indocyanine Green. Laser Coagulation. Male. Middle Aged. Visual Acuity. Vitrectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151500.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fluorocarbons; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


77. Hon SF, Wong GK, Zhu XL, Ng HK, Sin NC, Poon WS: Surgical treatment of a neonate with refractory seizures secondary to congenital giant cell astrocytoma: case report and literature review. Hong Kong Med J; 2006 Jun;12(3):222-4
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of a neonate with refractory seizures secondary to congenital giant cell astrocytoma: case report and literature review.
  • Most congenital brain tumours are neuro-ectodermal tumours and medulloblastomas; giant cell astrocytoma and other tuberous sclerosis-related tumours are rare.
  • Surgical resection was performed successfully and pathology revealed the tumour to be a giant cell astrocytoma.

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760552.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Number-of-references] 8
  •  go-up   go-down


78. Cadir B, Karahan N, Nasir S, Aydin MA, Turkaslan SS: Unusual synchronous presentation of maxillary sinus fibrosarcoma and gemistocytic astrocytoma with a complication called leukocytoclastic vasculitis: a case report. Eur J Dent; 2009 Jul;3(3):233-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual synchronous presentation of maxillary sinus fibrosarcoma and gemistocytic astrocytoma with a complication called leukocytoclastic vasculitis: a case report.
  • We report synchronous presentation of maxillary sinus fibrosarcoma and gemistocytic astrocytoma which is, to our knowledge, unique in the literature.
  • Both tumors metastases to other organ rarely and the metastatic spread of gemistocytic astrocytoma to fibrosarcoma or vice versa have also not been reported in the literature yet.
  • This report discusses the clinical course of the disease, outcome of the treatment approach and survival as well as an unusual occurrence of leukocytoclastic vasculitis during the course of radiotherapy in such unusual presentation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 1998 Jul;34(4):292-6 [9813725.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):1-7 [1624288.001]
  • [Cites] Br J Oral Maxillofac Surg. 1992 Apr;30(2):115-8 [1567797.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):399-406 [1993905.001]
  • [Cites] Medicine (Baltimore). 1988 Jul;67(4):220-30 [3292873.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Arthritis Care Res. 2000 Dec;13(6):417-23 [14635319.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1495-503 [11745227.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Feb;34(1):269-81 [11344078.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3735-41 [11268447.001]
  • [Cites] Eur J Surg Oncol. 2000 Mar;26(2):145-8 [10744932.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):198-200 [3276633.001]
  • (PMID = 19756200.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2741197
  • [Keywords] NOTNLM ; Fibrosarcoma / Gemistocytic astrocytoma / Leukocytoclastic vasculitis / Maxillary sinus / Radiotherapy / Synchronous cancer
  •  go-up   go-down


79. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T: MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res; 2010 Aug 15;16(16):4289-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance.
  • They are implicated in tumorigenesis and function both as tumor suppressors and as oncogenes.
  • The clinical significance of miRNA expression profiles in malignant gliomas remains unclear.
  • EXPERIMENTAL DESIGN: In this study, we examined the expression levels of 365 mature human miRNAs in 12 malignant gliomas, including 8 glioblastomas and 4 anaplastic astrocytomas, using TaqMan real-time quantitative PCR arrays.
  • A validation study was done to corroborate a subset of the results, including expression levels of miR-196a, -196b, -21, and -15b, by analyzing 92 malignant gliomas by conventional real-time PCR.
  • RESULTS: Expression profiles in glioblastomas and anaplastic astrocytomas suggested that 16 miRNAs were candidate markers associated with the malignant progression of gliomas.
  • Both miRNAs showed increased expression levels in glioblastomas relative to both anaplastic astrocytomas and normal brains in the validation study.
  • CONCLUSIONS: Our results suggest that miR-196 may play a role in the malignant progression of gliomas and may be a prognostic predictor in glioblastomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics. MicroRNAs / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601442.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN196 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


80. Butowski NA, Sneed PK, Chang SM: Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol; 2006 Mar 10;24(8):1273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of recurrent high-grade astrocytoma.
  • High-grade gliomas represent a significant source of cancer-related death, and usually recur despite treatment.
  • In this analysis of current brain tumor medicine, we review diagnosis, standard treatment, and emerging therapies for recurrent astrocytomas.
  • Difficulties in interpreting radiographic evidence, especially with regard to differentiating between tumor and necrosis, present a formidable challenge.
  • The most accurate diagnoses come from tissue confirmation of recurrent tumor, but a combination of imaging techniques, such as magnetic resonance spectroscopy imaging, may also be relevant for diagnosis.
  • We describe the use of conventional radiotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, and photodynamic therapy for recurrent high-grade glioma.
  • The treatment of this devastating disease has so far been met with limited success, but emerging knowledge of neuroscience and the development of novel therapeutic agents will likely give patients new options and require the neuro-oncology community to redefine clinical trial design and strategy continually.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Glioma / diagnosis. Glioma / therapy. Humans. Radiotherapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525182.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 87
  •  go-up   go-down


81. Lee WH, Jin JS, Tsai WC, Chen YT, Chang WL, Yao CW, Sheu LF, Chen A: Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma. Pathobiology; 2006;73(3):141-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma.
  • In nude mice, the growth of the tumor was inhibited by 30% by AS-CH or AS-AC (20 mg/kg; p < 0.05) and by 60% by AS-CH or AS-AC (60 mg/kg; p < 0.05).
  • CONCLUSIONS: Danggui may inhibit tumor growth by reducing the level of VEGF and the proapoptotic protein, cathepsin B.
  • Thus, danggui may be useful in the treatment of high-grade astrocytomas.
  • [MeSH-major] Angelica sinensis / chemistry. Antineoplastic Agents / pharmacology. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Phytotherapy
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cathepsin B / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Formazans / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Plant Extracts / pharmacology. Tetrazolium Salts / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085958.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Formazans; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 23305-68-2 / MTT formazan; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


82. Choi K, Han YH, Choi C: N-acetyl cysteine and caffeic acid phenethyl ester sensitize astrocytoma cells to Fas-mediated cell death in a redox-dependent manner. Cancer Lett; 2007 Nov 8;257(1):79-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-acetyl cysteine and caffeic acid phenethyl ester sensitize astrocytoma cells to Fas-mediated cell death in a redox-dependent manner.
  • In this study, we investigated the role of reactive oxygen species (ROS) in Fas-induced cell death in human astrocytoma cells.
  • These results collectively indicate that NAC and CAPE sensitize astrocytoma cells to Fas-induced apoptosis in a redox-dependent manner, suggesting a potential use in the treatment of malignant brain tumors.
  • [MeSH-major] Acetylcysteine / pharmacology. Antigens, CD95 / metabolism. Astrocytoma / drug therapy. Caffeic Acids / pharmacology. Oxidation-Reduction. Phenylethyl Alcohol / analogs & derivatives

  • Hazardous Substances Data Bank. 2-PHENYLETHANOL .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692455.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Caffeic Acids; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Reactive Oxygen Species; EC 3.4.22.- / Caspases; G960R9S5SK / caffeic acid phenethyl ester; ML9LGA7468 / Phenylethyl Alcohol; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


83. Nakasu S, Fukami T, Jito J, Matsuda M: Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol; 2007 Dec;68(6):603-8; discussion 608-9
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.
  • If loss of function in MGMT is related to tumor progression, the immunohistochemical method may predict the malignant change of gliomas.
  • METHOD: We investigated the expression of MGMT by immunohistochemical method in 28 supratentorial hemispheric diffuse astrocytomas.
  • RESULTS: There were 19 MGMT-positive and 9 MGMT-negative astrocytomas.
  • Two long-term survivors with MGMT-negative tumor responded well to nitrosourea-based chemotherapy and lived more than 8 years after malignant transformation.
  • CONCLUSION: Although the status of MGMT did not affect the overall survival, immunohistochemical evaluation of MGMT expression may be a good marker for tumor progression.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825378.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


84. Woźniak B, Woźniak A, Kasprzak HA, Drewa G, Mila-Kierzenkowska C, Drewa T, Planutis G: Lipid peroxidation and activity of some antioxidant enzymes in patients with glioblastoma and astrocytoma. J Neurooncol; 2007 Jan;81(1):21-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and activity of some antioxidant enzymes in patients with glioblastoma and astrocytoma.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Catalase / metabolism. Glioblastoma / metabolism. Malondialdehyde / metabolism. Superoxide Dismutase / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Erythrocytes / enzymology. Female. Free Radicals / metabolism. Humans. Male. Middle Aged. Reference Values

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773213.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Free Radicals; 4Y8F71G49Q / Malondialdehyde; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


85. Maciá Escalante S, Rodríguez Lescure A, Segura Ibáñez JM, Sáez Castán J, Guillén Ponce C, Carrato Mena A: Patient with resected anaplastic astrocytoma and an image suggestive of relapse. Clin Transl Oncol; 2006 Dec;8(12):912-4
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Edema / radiography. Brain Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169765.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


86. Beetz C, Brodoehl S, Patt S, Kalff R, Deufel T: Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma. Oncol Rep; 2005 Feb;13(2):335-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma.
  • The present study addressed expression of DBCCR1 in gliomas, specifically in astrocytomas, using semi-quantitative RT-PCR on 25 tumours of different malignancy grade and on 5 control brain tissue samples.
  • Genomic deletion of the DBCCR1 locus at 9q32-33 was also investigated, together with the CDKN2A locus at 9p21, by loss of heterozygosity analysis in a second series of 26 astrocytic tumours.
  • In contrast to the situation in bladder cancer, the prevalent inactivation of DBCCR1 seen at the expression level in astrocytomas is not primarily caused by genomic loss of the gene.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genes, Tumor Suppressor. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643521.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DBC1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


87. Bing F, Kremer S, Lamalle L, Chabardes S, Ashraf A, Pasquier B, Le Bas JF, Krainik A, Grand S: [Value of perfusion MRI in the study of pilocytic astrocytoma and hemangioblastoma: preliminary findings]. J Neuroradiol; 2009 May;36(2):82-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of perfusion MRI in the study of pilocytic astrocytoma and hemangioblastoma: preliminary findings].
  • [Transliterated title] Intérêt de l'imagerie de perfusion dans l'étude des astrocytomes pilocytiques et des hémangioblastomes : étude préliminaire.
  • PURPOSE: Pilocytic astrocytomas (PA) and hemangioblastomas (HB) can present the same morphological characteristics on conventional MRI sequences, most usually in the form of a cerebellar cystic mass with a mural nodule that strongly enhances on post-contrast T1 images.
  • The maximum relative cerebral blood volume (rCBV(max)), defined as the ratio between the CBV(max) in tumor tissue and the CBV in healthy, contralateral white matter, is considered to be indicative of the type of tumor.
  • [MeSH-major] Astrocytoma / diagnosis. Blood Volume. Brain / blood supply. Brain Neoplasms / diagnosis. Cerebrovascular Circulation. Hemangioblastoma / diagnosis. Magnetic Resonance Imaging / methods


88. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.
  • One year later, the anaplastic astrocytoma was found to have transformed into a glioblastoma multiforme.
  • These findings suggest that central neurocytoma or progenitor cells have the potential for oligodendrocytic and astrocytic transformation with different genetic aberrations.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Time Factors


89. Rovin RA, Winn R: Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. Case report. J Neurosurg Spine; 2007 May;6(5):447-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. Case report.
  • The authors report the case of a 28-year-old woman with a high-grade spinal cord astrocytoma.
  • Treatment using surgery, radiation, and temozolomide (TMZ) led to functional recovery and regression of the residual tumor as demonstrated on serial magnetic resonance images.
  • Genetic testing revealed that this tumor did not express the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).
  • This is the first report in the literature correlating MGMT expression with the clinical response of a high-grade spinal cord astrocytoma treated using TMZ.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / metabolism. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542512.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


90. Jiménez L, Correa-Rivas M, Colón-Castillo L, Rivera-Zengotita M, Colón G, Vigo J, McBurney E: Pilomyxoid astrocytoma in unusual location in a child with neurofibromatosis type 1: case report and review of the literature. P R Health Sci J; 2010 Jun;29(2):123-6
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pilomyxoid astrocytoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma in unusual location in a child with neurofibromatosis type 1: case report and review of the literature.
  • Pilomyxoid astrocytoma (PMA) is a recently defined brain tumor believed to be a variant of pilocytic astrocytoma (PA), but with a more aggressive course.
  • Despite the fact that most of PMAs occur in the hypothalamic region, high awareness should be given to lesions in unusual locations, thus expanding the current epidemiologically known locations for this tumor.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebral Ventricle Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neurofibromatosis 1

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496528.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Puerto Rico
  • [Number-of-references] 27
  •  go-up   go-down


91. Horger M, Beschorner R, Nägele T, Danz S, Ernemann U: [Pilocytic astrocytoma: imaging findings]. Rofo; 2009 Dec;181(12):1109-12
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilocytic astrocytoma: imaging findings].
  • [Transliterated title] Pilozytisches Astrozytom: Bildgebende Diagnostik.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Blood-Brain Barrier / physiology. Brain / pathology. Child. Contrast Media / administration & dosage. Diagnosis, Differential. Humans. Prognosis. Sensitivity and Specificity. Tumor Burden. Young Adult


92. Masri A, Bakri FG, Assaf A, Musharbash A, Haroun AA, Zak I: Intra-axial dermoid tumor mimicking pilocytic astrocytoma. Childs Nerv Syst; 2009 Apr;25(4):395-6
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-axial dermoid tumor mimicking pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology. Dermoid Cyst / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Childs Nerv Syst. 2008 Jan;24(1):157-9 [17657495.001]
  • (PMID = 19184043.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Germany
  •  go-up   go-down


93. Krzyszkowski T, Dziedzic T, Czepko R, Szczudlik A: Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res; 2008 Apr;30(3):294-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma.
  • OBJECTIVE: Glioma cells can produce anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta) which inhibit T cell and monocyte function.
  • It is unknown if production of these cytokines is limited to the site of tumor or these molecules are also released to cerebrospinal fluid and blood.
  • The goal of our study was to determine if patients with astrocytoma have increased levels of IL-10 and TGF-beta 2 in cerebrospinal fluid (CSF) and serum.
  • METHODS: CSF and serum samples were taken from 16 patients with astrocytoma of grade III or grade IV according to the WHO classification and from 28 age- and gender-matched controls (patients with normal pressure hydrocephalus or with lumbar disk herniation).
  • Patients with astrocytoma had decreased levels of IL-10 (0.9 +/- 1.2 versus 3.5 +/- 9.2 pg/ml, p=0.01) and TGF-beta 2 (0.0 +/- 0.0 versus 5.4 +/- 9.4 pg/ml, p=0.05) in CSF compared to controls.
  • Because serum IL-10 and TGF-beta 2 levels are similar in patients with astrocytoma and in controls, these cytokines are probably not directly involved in peripheral monocyte and T cell deactivation.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / cerebrospinal fluid. Interleukin-10 / blood. Interleukin-10 / cerebrospinal fluid. Transforming Growth Factor beta2 / blood. Transforming Growth Factor beta2 / cerebrospinal fluid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848206.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta2; 130068-27-8 / Interleukin-10
  •  go-up   go-down


94. Tuominen H, Lohi J, Maiche A, Törmänen J, Baumann P: Mediastinal metastasis of glioblastoma multiforme evolving from anaplastic astrocytoma. J Neurooncol; 2005 Nov;75(2):225-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal metastasis of glioblastoma multiforme evolving from anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Disease Progression. Fatal Outcome. Follow-Up Studies. Gene Deletion. Genes, p16. Glial Fibrillary Acidic Protein / metabolism. Homozygote. Humans. Male. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy. Survival Analysis. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132499.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


95. Linscott LL, Osborn AG, Blaser S, Castillo M, Hewlett RH, Wieselthaler N, Chin SS, Krakenes J, Hedlund GL, Sutton CL: Pilomyxoid astrocytoma: expanding the imaging spectrum. AJNR Am J Neuroradiol; 2008 Nov;29(10):1861-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma: expanding the imaging spectrum.
  • BACKGROUND AND PURPOSE: Pilomyxoid astrocytoma (PMA) is a recently described variant of pilocytic astrocytoma (PA) with unique clinical and histopathologic characteristics.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / diagnosis. Brain Neoplasms / classification. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701580.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


96. Raspall-Chaure M, Vizmanos-Lamotte D, Auger-Acosta C, Tallada-Serra M: [Gelastic seizures and low-grade hypothalamic astrocytoma]. Rev Neurol; 2006 Sep 1-15;43(5):312-4
Genetic Alliance. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gelastic seizures and low-grade hypothalamic astrocytoma].
  • [Transliterated title] Crisis gelasticas y astrocitoma hipotalamico de bajo grado.
  • [MeSH-major] Astrocytoma. Epilepsies, Partial / etiology. Hamartoma. Hypothalamic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16941432.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


97. Tsuji K, Nakasu S, Tsuji A, Fukami T, Nozaki K: [Postoperative regression of desmoplastic infantile astrocytoma]. No Shinkei Geka; 2008 Nov;36(11):1035-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative regression of desmoplastic infantile astrocytoma].
  • Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) is a rare tumor that is usually located superficially with a large cystic component.
  • In rare cases, postoperative regression of the residual tumor has been reported.
  • A CT scan showed a large cystic tumor in his left parieto-occipital lobe.
  • The histopathological examination revealed an astrocytic tumor with marked desmoplasia.
  • In the central portion of the tumor, anaplastic features, such as necrosis, mitosis, and high nucleus-cytoplasmic ratio, were noticed.
  • Six months later when he was admitted for the second-stage surgery, MRI showed regression of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery
  • [MeSH-minor] Gliosis. Humans. Infant. Male. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048924.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


98. Marsh J, Mukherjee P, Seyfried TN: Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res; 2008 Dec 1;14(23):7751-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma.
  • PURPOSE: Malignant astrocytomas exhibit constitutive Akt phosphorylation due to reduced phosphatase and tensin homologue (PTEN) tumor suppressor expression or to increased growth factor receptor tyrosine kinase activation.
  • Many astrocytomas are also tuberous sclerosis complex 2 (TSC2) protein deficient and exhibit constitutive mammalian target of rapamycin (mTOR) activity.
  • Astrocytomas harboring PTEN/Akt/TSC2 pathway mutations are dependent on glycolysis to satisfy their bioenergetic requirements.
  • Therapies that disrupt energy homeostasis can potentially manage astrocytoma growth and progression.
  • Although dietary restriction (DR) reduces glycolysis and manages early-stage astrocytoma growth, no prior studies have identified the mechanisms involved or determined if DR can also manage late-stage tumor growth.
  • EXPERIMENTAL DESIGN: The effects of a late-onset intermittent DR feeding paradigm were examined in adult C57BL/6J mice bearing the syngeneic CT-2A malignant astrocytoma grown orthotopically or subcutaneously.
  • DR initiated 10 to 14 days after tumor implantation (late onset) reduced CT-2A growth, delayed malignant progression, and significantly extended survival.
  • CONCLUSIONS: Our findings indicate that IGF-I/Akt signaling is associated with the antiapoptotic and glycolytic phenotype of the CT-2A astrocytoma and that DR targets this pathway.
  • Our findings highlight the efficacy of late-onset DR in managing astrocytoma growth and suggest that DR may be an effective broad-spectrum inhibitor of Akt signaling in PTEN/TSC2-deficient astrocytomas.
  • [MeSH-major] Astrocytoma / diet therapy. Brain Neoplasms / diet therapy. PTEN Phosphohydrolase / deficiency. Proto-Oncogene Proteins c-akt / metabolism. Tumor Suppressor Proteins / deficiency

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047102.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102135; United States / NINDS NIH HHS / NS / NS 055195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


99. Ulu MO, Tanriöver N, Biçeroğlu H, Oz B, Canbaz B: A case report: a noninfantile desmoplastic astrocytoma. Turk Neurosurg; 2008 Jan;18(1):42-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report: a noninfantile desmoplastic astrocytoma.
  • INTRODUCTION AND CASE DESCRIPTION: Desmoplastic infantile astrocytomas (DIA) are rare intracranial tumors of infancy with distinctive clinical and radiological features.
  • CONCLUSION: Although accepted as a tumor of infancy, DIA can also be encountered in older patients.
  • Careful diagnosis and differentiation of DIA cases with other tumors, particularly malignant astrocytomas is important since the therapeutic strategies may differ.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382977.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


100. You H, Kim YI, Im SY, Suh-Kim H, Paek SH, Park SH, Kim DG, Jung HW: Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma. J Neurooncol; 2005 Aug;74(1):1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma.
  • For investigation of histogenesis of central neurocytomas (CNs), subependymoma (SEs), subependymal giant cell astrocytomas (SEGAs), we studied expression of various neuronal and glial biomarkers by immunohistochemical (IHC) study and reverse transcriptase-polymerase chain reaction (RT-PCR).
  • Control group was five ependymomas (EPs) and four pilocytic astrocytomas (PAs).
  • Conclusively, coexpression of neuronal and glial markers and expression of nestin in CNs, SEGAs and SEs suggested the origin of these tumor cells might be the stem cells being able to differentiate into both neuronal and glial phenotypes.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Glioma, Subependymal / metabolism. Neurocytoma / metabolism






Advertisement